Aspira Women's Health (AWH) 10-K 29 Mar 24 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Mar. 28, 2024	Jun. 30, 2023
Document And Entity Information [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Current Fiscal Year End Date	--12-31
Entity File Number	001-34810
Entity Registrant Name	Aspira Women’s Health Inc.
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	33-0595156
Entity Address Address Line 1	12117 Bee Caves Road
Entity Address Address Line 2	Building III
Entity Address Address Line 3	Suite 100
Entity Address City Or Town	Austin
Entity Address State Or Province	TX
Entity Address Postal Zip Code	78738
City Area Code	512
Local Phone Number	519-0400
Security 12b Title	Common Stock, par value $0.001 per share
Trading Symbol	AWH
Security Exchange Name	NASDAQ
Entity Well Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Icfr Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 17,677,058
Entity Common Stock, Shares Outstanding		12,344,104
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Central Index Key	0000926617
Amendment Flag	false
Document Fin Stmt Error Correction Flag	false
Documents Incorporated by Reference	Certain information from the registrant’s Definitive Proxy Statement for its 2024 Annual Meeting of Stockholders is incorporated by reference into Part III of this report.
Auditor Name	BDO USA, P.C
Auditor Location	Boston, Massachusetts
Auditor Firm Id	243

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,597	$ 13,306
Accounts receivable, net of reserves of $15 and $9, as of December 31, 2023 and December 31, 2022, respectively	1,459	1,245
Prepaid expenses and other current assets	997	1,442
Inventories	227	316
Total current assets	5,280	16,309
Property and equipment, net	165	368
Right-of-use assets	528	282
Restricted cash	258	251
Other assets	31	163
Total assets	6,262	17,373
Current liabilities:
Accounts payable	1,261	881
Accrued liabilities	2,863	3,402
Current portion of long-term debt	166	403
Short-term debt	670	764
Current maturities of lease liabilities	159	77
Total current liabilities	5,119	5,527
Non-current liabilities:
Long-term debt	1,430	2,315
Non-current maturities of lease liabilities	427	272
Warrant liabilities	1,651	2,280
Total liabilities	8,627	10,394
Commitments and contingencies (Note 6)
Stockholders’ (deficit) equity:
Common stock, par value $0.001 per share, 200,000,000 and 150,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 10,645,049 and 8,306,326 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	11	8
Additional paid-in capital	515,927	508,584
Accumulated deficit	(518,303)	(501,613)
Total stockholders’ (deficit) equity	(2,365)	6,979
Total liabilities and stockholders’ (deficit) equity	$ 6,262	$ 17,373

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Consolidated Balance Sheets [Abstract]
Accounts receivable, allowance	$ 15	$ 9
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	150,000,000
Common stock, shares issued	10,645,049	8,306,326
Common stock, shares outstanding	10,645,049	8,306,326

Consolidated Statements Of Oper

Consolidated Statements Of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Revenue	$ 9,154	$ 8,184
Cost of revenue:
Cost of revenue	3,892	3,861
Gross profit	5,262	4,323
Operating expenses:
Research and development	4,035	5,917
Sales and marketing	7,812	14,915
General and administrative	12,267	14,629
Total operating expenses	24,114	35,461
Loss from operations	(18,852)	(31,138)
Other income (expense), net:
Change in fair value of warrant liabilities	629	1,704
Interest income, net	48	17
Forgiveness of DECD loan	1,000
Other income (expense), net	485	(468)
Total other income (expense), net	2,162	1,253
Net loss	$ (16,690)	$ (29,885)
Net loss per share - basic	$ (1.81)	$ (3.85)
Net loss per share - diluted	$ (1.81)	$ (3.85)
Weighted average common shares used to compute basic net loss per common share	9,233,306	7,769,109
Weighted average common shares used to compute diluted net loss per common share	9,233,306	7,769,109
Product [Member]
Revenue:
Revenue	$ 9,153	$ 7,970
Cost of revenue:
Cost of revenue	3,892	3,694
Genetics [Member]
Revenue:
Revenue	$ 1	214
Cost of revenue:
Cost of revenue		$ 167

Consolidated Statements Of Chan

Consolidated Statements Of Changes In Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital	Accumulated Deficit	Total
Balance, shares at Dec. 31, 2021	7,475,916
Balance at Dec. 31, 2021	$ 7	$ 501,893	$ (471,728)	$ 30,172
Net loss			(29,885)	(29,885)
Common stock issued in conjunction with exercise of stock options, shares	1,533
Common stock issued in conjunction with exercise of stock options		13		13
Common stock and warrants issued in conjunction with follow-on public offering, net of issuance costs, shares	800,000
Common stock and warrants issued in conjunction with follow-on public offering, net of issuance costs	$ 1	4,265		4,266
Common stock issued for vested restricted stock awards, shares	28,877
Common stock issued for vested restricted stock awards		362		362
Stock-based compensation expense		2,051		2,051
Balance, shares at Dec. 31, 2022	8,306,326
Balance at Dec. 31, 2022	$ 8	508,584	(501,613)	6,979
Net loss			(16,690)	(16,690)
Common stock issued under an at the market offering agreement, net of issuance costs, shares	35,552
Common stock issued under an at the market offering agreement, net of issuance costs		68		68
Common stock issued for equity line of credit, net of issuance costs, shares	360,943
Common stock issued for equity line of credit, net of issuance costs		1,177		1,177
Common stock issued for entering into equity line of credit, line of credit with Lincoln Park (shares)	47,733
Common stock issued for entering into equity line of credit with Lincoln Park		258		258
Common stock issued under a registered direct offering, net of issuance costs, shares	1,694,820
Common stock issued under a registered direct offering, net of issuance costs	$ 2	4,117		4,119
Common stock issued for vested restricted stock awards, shares	199,699
Common stock issued for vested restricted stock awards	$ 1	814		815
Stock-based compensation expense		909		909
Fractional shares adjustment related to reverse stock split	(24)
Balance, shares at Dec. 31, 2023	10,645,049
Balance at Dec. 31, 2023	$ 11	$ 515,927	$ (518,303)	$ (2,365)

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (16,690)	$ (29,885)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash lease expense	(9)	4
Depreciation and amortization	199	264
Stock-based compensation expense	1,724	2,414
Change in fair value of warrant liabilities	(629)	(1,704)
Other expenses representing transaction costs allocated to the issuance of warrants		574
Loss on impairment and disposal of property and equipment	28	64
Forgiveness of DECD loan	(1,000)
Financing expense for entering into equity line of credit with Lincoln Park	258
Changes in operating assets and liabilities:
Accounts receivable	(214)	(218)
Prepaid expenses and other assets	577	33
Inventories	89	(142)
Accounts payable	380	(620)
Accrued liabilities	(539)	(1,838)
Other liabilities	(68)	(14)
Net cash used in operating activities	(15,894)	(31,068)
Cash flows from investing activities:
Purchase of property and equipment	(24)	(232)
Net cash used in investing activities	(24)	(232)
Cash flows from financing activities:
Principal repayment of DECD loan	(148)	(261)
Proceeds from issuance of common stock from exercise of stock options		13
Proceeds from at the market offering	202
Payment of issuance costs for at the market offering	(134)
Proceeds from equity line of credit	1,177
Proceeds from registered direct offering	4,716
Payment of issuance costs for registered direct offering	(597)
Proceeds from public offering		9,000
Payment of issuance costs for public offering		(1,325)
Net cash provided by financing activities	5,216	7,427
Net decrease in cash, cash equivalents and restricted cash	(10,702)	(23,873)
Cash, cash equivalents and restricted cash, beginning of year	13,557	37,430
Cash, cash equivalents and restricted cash, end of year	2,855	13,557
Reconciliation to Consolidated Balance Sheet:
Cash and cash equivalents	2,597	13,306
Restricted cash	258	251
Unrestricted and restricted cash and cash equivalents	2,855	13,557
Supplemental disclosure of cash flow information:
Cash paid for interest	45	77
Supplemental disclosure of noncash investing and financing activities:
Net increase in right-of-use assets	$ 318
Fair value of warrants issued in conjunction with common stock offering		$ 3,984

Basis Of Presentation And Summa

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies	12 Months Ended
	Dec. 31, 2023
Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies [Abstract]
Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies	NOTE 1: Basis of Presentation and Summary of Significant Accounting and Reporting Policies Organization and Basis of Presentation Aspira Women’s Health Inc., formerly known as Vermillion, Inc. (“Aspira,” and together with its wholly-owned subsidiaries, the “Company ”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company currently markets and sells the following products and related services: (1) the Ova1Plus workflow, which uses Ova1, a qualitative serum test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical and radiological evaluation does not indicate malignancy, as the primary test and Overa, a second-generation biomarker test intended to maintain Ova1’s high sensitivity while improving specificity, as a reflex for Ova1 intermediate range results, leveraging the strengths of Ova1’s MIA sensitivity and Overa’s (MIA2G) specificity to reduce incorrectly elevated results; and (2) OvaWatch, an LDT intended to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. Overa is currently not offered except as a reflex test performed as part of the Ova1Plus workflow. Collectively, these tests are referred to and marketed as OvaSuite. For the year ended December 31, 2023, the Company’s product and related revenue was limited to these products, and Aspira GenetiX, which was discontinued in the third quarter of 2022. The Company’s products are distributed through its own national sales force, through its proprietary decentralized testing platform and cloud service marketed as Aspira Synergy, and through marketing and distribution agreements with BioReference Health, LLC and ARUP Laboratories. Going Concern The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $ 518.3 million and working capital of $ 0.2 million as of December 31, 2023. For the year ended December 31, 2023, the Company incurred a net loss of $ 16.7 million and used cash in operations of $ 15.9 million. The Company also expects to incur a net loss and negative cash flows from operations for 2024. In order to continue our operations as currently planned through 2024 and beyond, the Company will need to raise additional capital. The Company expects to take further action to protect its liquidity position. Such actions may include, but are not limited to:  Raising capital through an equity offering either in the public markets or via a private placement offering (to the extent that the Company raises additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. However, no assurance can be given that capital will be available on acceptable terms, or at all) ;  Securing debt, however, no assurance can be given that debt will be available on acceptable terms or at all;  Reducing executive bonuses or replacing cash compensation with equity grants;  Reducing professional services and consulting fees and eliminating non-critical projects;  Reducing travel and entertainment expenses; and  Reducing, eliminating or deferring discretionary marketing programs. The Company also has outstanding warrants to purchase shares of its common stock that may be exercised; although there can be no assurance that the warrants will be exercised. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. Management expects cash from product sales and licensing to be the Company’s only material, recurring source of cash in 2024. Given the above conditions, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are filed. The consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. On June 1, 2022, the Company received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market stating that, for the preceding 30 consecutive business days, the closing bid price for Aspira common stock was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). On November 29, 2022, the Company was granted an additional 180-calendar day compliance period, or until May 29, 2023, to regain compliance with the minimum bid price requirement. On May 26, 2023, the Company received notice from Nasdaq that it had regained compliance. On July 11, 2023, the Company received a second deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that, for the 30 consecutive business days prior to the date of the deficiency letter, the Company’s Market Value of Listed Securities was below the minimum of $ 35 million requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq provided the Company with 180 calendar days, or until January 8, 2024, to regain compliance with the MVLS Requirement. On September 12, 2023, the Company received notice from Nasdaq that it had regained compliance. T here is no assurance that the Company will maintain compliance with the MVLS Requirement or any of the other Nasdaq continued listing requirements. Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated in consolidation . Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company’s equity awards, warrants, income taxes and contingent liabilities. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes. Highly liquid investments that are considered cash equivalents include money market funds. Restricted Cash Restricted cash consists of a security deposit for a credit card financing arrangement. The restriction on the cash will be removed when the Company closes its credit card account. Fair Value Measurement Accounting Standards Codification (“ASC”) Topic 820, Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. Financial instruments of the Company consist primarily of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, debt and warrant liability. Cash and cash equivalents, restricted cash, accounts receivable, and accounts payable are considered Level 1 due to their short-term nature and their market interest rates. Warrant liability is considered Level 2 and is recorded at fair value at the end of each reporting period. Debt is considered Level 3, which the Company does not record at fair value. Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of $250,000 but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities. Accounts Receivable Virtually all accounts receivable are derived from sales made to customers located in North America. The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The Company maintains an allowance for credit losses based upon the expected collectability of accounts receivable, such as the historical collection cycle. Amounts are written off against the allowances for credit losses when the Company determines that a customer account is not collectable. We believe our exposure to concentrations of credit risk is limited due to the diversity of our payer base. Inventory The Company has inventory consisting primarily of kit inventory for specimen delivery as well as reagents used for specimen testing and miscellaneous inventory such as pipettes, gloves and other non-reagent items. At each reporting period the Company reviews its inventories for obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realized value, which is primarily related to kit inventory when kits expire. Inventory is valued at cost using the first-in-first-out method. Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years . Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized. Revenue Recognition Product Revenue – OvaSuite: The Company recognizes product revenue in accordance with the provisions of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Product revenue is recognized upon completion of the OvaSuite test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year. The effect of any change made to an estimated input component and, therefore revenue recognized, would be recorded as a change in estimate at the time of the change. The Company also reviews its patient account population and determines an appropriate distribution of patient accounts by payer (i.e., Medicare, patient pay, other third-party payer, etc.) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. During the years ended December 31, 2023 and 2022, there were no material adjustments to estimates of variable consideration to derecognize revenue for services provided in a prior period. There were no impairment losses on accounts receivable recorded during the years ended December 31, 2023 and 2022. Genetics Revenue – Aspira GenetiX: Under ASC 606, the Company’s genetics revenue was recognized upon completion of the Aspira GenetiX test and delivery of results to the physician based on estimates of amounts that would ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considered factors such as payment history and amount, payer coverage, whether there was a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates required significant judgment by management as the Company has limited experience with such factors relating to Aspira GenetiX. In September 2022, the Company received a notice of cancellation from its only Aspira Synergy genetics carrier screening customer, Axia Women’s Health. As a result of this cancellation, along with the general deterioration of commercial opportunities in the genetics carrier screening market, has led the Company to cease providing Aspira GenetiX, including genetics carrier screening, on the Aspira Synergy platform, effective as of September 30, 2022. The Company did not incur any termination penalties nor did the Company accrue any expenses as a result of the cancellation. This did not have a material impact on Company revenues in 2022 or 2023, nor does management expect it to have a material impact in any future periods. Research and Development Costs Research and development costs are expensed as incurred. Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on behalf of the Company. In addition, acquisitions of assets to be consumed in research and development, with no alternative future use, are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established. Patent Costs Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within general and administrative expenses on the Consolidated Statements of Operations. Such costs aggregated to approximately $ 341,000 and $ 410,000 for the years ended December 31, 2023 and 2022, respectively. Stock-Based Compensation The Company records the fair value of non-cash stock-based compensation costs for stock options related to the 2019 Stock Incentive Plan (“2019 Plan”). The Company estimates the fair value of stock options using a Black-Scholes option valuation model. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment. The Company uses the straight-line method to amortize the fair value over the requisite service period of the award, which is generally equal to the vesting period. The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding. This data includes employees’ expected exercise and post-vesting employment termination behaviors. The expected stock price volatility is estimated using Company historical volatility in deriving the expected volatility assumption . The Company made an assessment that Company historic volatility is most representative of future stock price trends. The expected dividend yield is based on the estimated annual dividends that are expected to be paid over the expected life of the options as a percentage of the market value of the Company’s common stock as of the grant date. The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date. The Company records stock-based compensation net of estimated forfeitures. 2023 Reverse Stock Split At the Company’s annual meeting on May 9, 2023, the stockholders of the Company approved the proposal to authorize the Board of Directors in its discretion, without further authorization of the Company’s stockholders, to amend the Company’s Certificate of Incorporation to effect a reverse split of the Company’s common stock by a ratio of between one-for-ten and one-for-twenty. On May 9, 2023, the Company’s board of directors approved a one-for-fifteen reverse stock split of the Company’s common stock without any change to its par value, which became effective on May 12, 2023. All references to share and per share amounts for all periods presented in these consolidated financial statements have been retrospectively restated to reflect the Reverse Stock Split and proportional adjustment of the preferred stock conversion ratio. Par values were not adjusted. Government Assistance On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). One provision within the CARES Act provided an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable tax credit against the employer share of Social Security tax equal to 50% of the qualified wages paid to employees from March 13, 2020 through December 31, 2020. The ERC was subsequently expanded in 2021 for employers to claim a refundable tax credit for 70% of the qualified wages paid to employees from January 1, 2021 through September 30, 2021. The Company qualified for federal government assistance through the ERC. In August 2023, we received approximately $ 347,000 from the Internal Revenue Service for payroll tax refunds for 2020. The Company recorded the receipt as other income in its consolidated statements of operations. Contingencies The Company accounts for contingencies in accordance with ASC 450 Contingencies (“ASC 450”) which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Management believes that the Company’s accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized. ASC Topic 740, Accounting for Uncertainty in Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure. The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets. Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalent shares outstanding during the period. Common stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share. Fair Value of Financial Instruments Financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrants and debt. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments. The carrying amount of restricted cash represents a long-term security deposit for a financial arrangement that is at cost. The carrying value of warrants is their fair value at the end of the period. The carrying value of debt approximates fair value due to its interest rate approximating market rates of interest available to the Company for similar instruments. Leases The Company determines if a contract, at its inception, is a lease or contains a lease based on whether the contract conveys the right to control the use of identified property, plant, or equipment (an identified asset) for a period of time in exchange for consideration. To determine whether a contract conveys the right to control the use of an identified asset for a period of time, the Company assesses whether, throughout the period of use, it has both the right to obtain substantially all of the economic benefits from use of the identified asset, and the right to direct the use of the identified asset. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease the Company (i) identifies lease and non-lease components, (ii) determines the consideration in the contract, (iii) determines whether the lease is an operating or financing lease; and (iv) recognizes lease right-of-use assets and liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and as such, the Company uses an incremental borrowing rate based on the information available at the lease commencement date, which represents a rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include items such as maintenance, utilities, or other operating costs. For leases of real estate, the Company combines the lease and associated non-lease components in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs. Additionally, the Company has elected the short-term lease exemption and, therefore, does not recognize a right-of-use asset or corresponding liability for lease arrangements with an original term of 12 months or less. Operating leases are included in right-of-use operating assets, current lease liabilities, and noncurrent lease liabilities in the consolidated balance sheet as of December 31, 2023 and 2022. Segment Reporting The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM evaluates the business on a consolidated basis and therefore, the Company operates one operating and reportable segment.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2023
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	NOTE 2: Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . This ASU requires timelier recording of credit losses on loans and other financial instruments held. Instead of reserves based on a current probability analysis, Topic 326 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. All organizations will now use forward-looking information to better inform their credit loss estimates. Topic 326 requires enhanced disclosures regarding significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization’s portfolio. These disclosures include qualitative and quantitative requirements that provide information about the amounts recorded in the financial statements. In addition, Topic 326 amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326 Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments , to introduce amendments which will affect the recognition and measurement of financial instruments, including derivatives and hedging. In May 2019, the FASB issued ASU No. 2019-05, Financial Instruments – Credit Losses (Topic 326); Targeted Transition Relief. The amendments in this ASU provide entities that have certain instruments within the scope of Subtopic 326-20 with an option to irrevocably elect the fair value option in Subtopic 825-10, applied on an instrument-by-instrument basis for eligible instruments upon adoption of Topic 326. This standard and related amendments are effective for the Company’s fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The ASU was effective January 1, 2023 for smaller reporting companies, which includes the Company. The Company adopted the new standard on January 1, 2023. The adoption of ASU 2016-13 did not have any impact on the Company’s results of operations, financial position, or cash flows. In March 2020, the FASB issued ASU No. 2020-03, Codification Improvements to Financial Instruments . This ASU improves and clarifies various financial instruments topics, including the current expected credit losses standard issued in 2016 (ASU No. 2016-13). The ASU includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The amendments have different effective dates. The issues 1-5 are conforming amendments, which are effective upon issuance of this final update. The Company determined that issues 1-5 have no impact on its financials. The amendments related to issue 6 and 7 affect ASU No. 2016-13, Financial instruments – credit losses (Topic 326): measurement of credit losses on financial statements . Effective dates of issue 6 and 7 were the same as the effective date of ASU No. 2016-13. The Company adopted the new standard on January 1, 2023. The adoption of this standard did not have a material impact on the Company’s results of operations, financial position, or cash flows . In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). This update was issued to assist in simplifying the accounting for convertible instruments. This ASU is scheduled to be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company does not expect this standard to have a material impact on its consolidated results of operations, financial position, or cash flows. In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”) to clarify guidance in Topic 820 on the fair value measurement of an equity security that is subject to a contractual sale restriction and also requires specific disclosures related to an equity security. ASU 2022-03 is scheduled to be effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect a material impact as a result of this standard on its results of operations, financial position, or cash flows. In March 2023, the FASB issued ASU No. 2023-01, Leases (Topic 842): Common Control Arrangements (“ASU 2023-01”) . ASU 2023-01 clarified the accounting for leasehold improvements for leases under common control. The guidance is scheduled to be effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. Early adoption is permitted. The Company is in the process of evaluating the potential impact of the adoption of this standard on its results of operations, financial position, or cash flows. In October 2023, the FASB issued ASU No. 2023-06, D isclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative (“ASU 2023-06”). The amendments in this ASU are expected to clarify or improve disclosure and presentation requirements of a variety of ASC topics by aligning them with the SEC’s regulations. ASU 2023-06 will become effective for each amendment on the effective date of the SEC's corresponding disclosure rule changes. The Company does not expect ASU 2023-06 will have a material impact on its results of operations, financial position, or cash flows. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. This ASU requires disclosure of significant segment expenses that are regularly provided to the CODM and included within the reported measure of a segment’s profit or loss, requires interim disclosures about a reportable segment’s profit or loss and assets that are currently required annually, requires disclosure of the position and title of the CODM, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, and contains other disclosure requirements. ASU 2023-07 is scheduled to be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is in the process of evaluating the potential impact the adoption of ASU 2023-07 will have a material its results of operations, financial position, or cash flows. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The Company does not expect ASU 2023-09 will have a material impact on its results of operations, financial position, or cash flows.

Strategic Alliance With Quest D

Strategic Alliance With Quest Diagnostics Incorporated	12 Months Ended
	Dec. 31, 2023
Strategic Alliance With Quest Diagnostics Incorporated [Abstract]
Strategic Alliance With Quest Diagnostics Incorporated	NOTE 3: Strategic Alliance with Quest Diagnostics Incorporated In March 2015, the Company reached an agreement with Quest Diagnostics Incorporated (“Quest Diagnostics”). Pursuant to this agreement, all Ova1 U.S. testing services for Quest Diagnostics customers were transferred to Aspira’s wholly-owned subsidiary, Aspira Labs, as of August 2015. Pursuant to this agreement, as amended as of December 8, 2022, Quest Diagnostics has continued to provide blood draw and logistics support by transporting specimens to Aspira Labs for testing and is billed by Quest Diagnostics for services performed. The purpose of the 2022 amendment was to add OvaWatch to the U.S testing services for Quest Diagnostics customers and to extend the term of the agreement from March 11, 2023 to December 31, 2023. Under the terms of the agreement, as amended, the Company is required to pay an annual fee of $ 75,000 for the services of a part-time Quest Diagnostics project manager. The parties are continuing to operate under the existing agreement. As of December 31, 2023, the Company has $ 346,820 accrued and payable to Quest Diagnostics for phlebotomy services rendered on behalf of the Company under the terms of the agreements.

Property And Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2023
Property And Equipment [Abstract]
Property And Equipment	Note 4: Property and Equipment The components of property and equipment as of December 31, 2023 and 2022 were as follows : Estimated December 31, (in thousands) Useful Life 2023 2022 Machinery and equipment 3 - 5 years $ 363 $ 891 Computer equipment and software 3 years 1,377 1,386 Furniture and fixtures 5 years 189 181 Leasehold improvements (1) 52 721 Gross property and equipment 1,981 3,179 Accumulated depreciation and amortization ( 1,816 ) ( 2,811 ) Property and equipment, net $ 165 $ 368 (1) Lesser of remaining lease term or estimated useful life Depreciation expense for property and equipment was $ 199,000 and $ 265,000 for the years ended December 31, 2023 and 2021, respectively. As of December 31, 2022, property and equipment was reviewed for potential impairment for recoverability by comparing the carrying amount of certain of the Company’s assets to the estimated undiscounted future cash flows expected to be generated by the asset group. As the carrying amount of the Company’s asset group exceeded its estimated undiscounted future cash flows, the Company recognized an impairment of $ 52,000 , recorded as selling, general and administrative expense on the consolidated statement of operations, based on the difference between the carrying value of the fixed assets and their fair value as of December 31, 2022 as a result of the Company’s discontinuance of the genetics testing offering effective September 30, 2022. The fair value was derived from an offer to purchase certain of the Company’s assets for a blanket amount, as the Company’s management believed it represented the most appropriate fair value of the asset group. There were no impairment charges for the year ended December 31, 2023.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2023
Accrued Liabilities [Abstract]
Accrued Liabilities	NOTE 5: Accrued Liabilities The components of accrued liabilities as of December 31, 2023 and 2022 were as follows: December 31, December 31, (in thousands) 2023 2022 Payroll and benefits related expenses $ 1,189 $ 1,803 Collaboration and research agreements expenses 217 404 Professional services 951 556 Other accrued liabilities 506 639 Total accrued liabilities $ 2,863 $ 3,402

Commitments, Contingencies And

Commitments, Contingencies And Debt	12 Months Ended
	Dec. 31, 2023
Commitments, Contingencies And Debt [Abstract]
Commitments, Contingencies And Debt	NOTE 6: Commitments, Contingencies and debt Loan Agreement On March 22, 2016, the Company entered into a loan agreement (as amended, the “DECD Loan Agreement”) with the DECD, pursuant to which the Company may borrow up to $ 4,000,000 from the DECD. The loan bears interest at a fixed rate of 2.0 % per annum and requires equal monthly payments of principal and interest until maturity, which would have occurred on April 15, 2026 . As security for the loan, the Company has granted the DECD a blanket security interest in the Company’s personal and intellectual property. The DECD’s security interest in the Company’s intellectual property may be subordinated to a qualified institutional lender. The loan may be prepaid at any time without premium or penalty. An initial disbursement of $ 2,000,000 was made to the Company on April 15, 2016 under the DECD Loan Agreement. On December 3, 2020, the Company received a disbursement of the remaining $ 2,000,000 under the DECD Loan Agreement, as the Company had achieved the target employment milestone necessary to receive an additional $ 1,000,000 under the DECD Loan Agreement and the DECD determined to fund the remaining $ 1,000,000 under the DECD Loan Agreement after concluding that the required revenue target would likely have been achieved in the first quarter of 2020 in the absence of the impacts of COVID-19. Under the terms of the DECD Loan Agreement, the Company was eligible for forgiveness of up to $ 1,500,000 of the principal amount of the loan if it was able to achieve certain job creation and retention milestones by December 31, 2022. On June 26, 2023, the Company was notified by the DECD that the Company satisfied all job creation and retention requirements under the loan agreement to receive forgiveness of $ 1,000,000 . During the year ended December 31, 2023, the Company recorded the $ 1,000,000 as other income in the statement of operations. If the Company fails to maintain its Connecticut operations through March 22, 2026, the DECD may require early repayment of a portion or all of the loan plus a penalty of 5 % of the total funded loan. On June 6, 2023, the Company was granted a deferral of interest and principal payments on a portion of the remaining outstanding balances through December 1, 2023. On January 30, 2024, the Company was granted an additional deferral of interest and principal payments on a portion of the remaining outstanding balances through June 1, 2024. The Company determined the loan deferrals met the definition of a troubled debt restructuring under ASC 470-60, Troubled Debt Restructurings by Debtors , as the Company was experiencing financial difficulties and the lenders granted a concession. The future undiscounted cash flows of the DECD loan after the loan deferrals exceeded the carrying value of the DECD loan prior to the loan deferrals. As such no gain was recognized as a result of the deferrals. Long-term debt consisted of the following: December 31, December 31, 2023 2022 (in thousands) DECD loan, net of issuance costs $ 1,596 $ 2,718 Less: Current portion, net of issuance costs ( 166 ) ( 403 ) Total long-term debt, net of issuance costs $ 1,430 $ 2,315 As of December 31, 2023, the annual amounts of future minimum principal payments due under the Company’s contractual obligation are shown in the table below. Unamortized debt issuance costs for the DECD loan were $ 8,000 . Debt related to the insurance promissory note of $ 670,000 , as described below, is not included in the following table due to the insurance promissory note being cancelable. Payments Due by Period (in thousands) Total 2024 2025 2026 2027 2028 Thereafter DECD Loan $ 1,604 $ 170 $ 335 $ 342 $ 215 $ 129 $ 413 Total $ 1,604 $ 170 $ 335 $ 342 $ 215 $ 129 $ 413 The DECD loan is classified within Level 3 of the fair value hierarchy. The following table presents the carrying value and fair value of the DECD loan. The fair value is estimated based on the discounted cash flows using the prevailing marketing interest rates. December 31, December 31, 2023 2022 (in thousands) Fair Value Hierarchy Carrying Value Fair Value Carrying Value Fair Value DECD loan Level 3 $ 1,604 $ 1,255 $ 2,729 $ 2,110 Insurance Notes During 2023 and 2022, the Company entered into insurance promissory notes for the payment of insurance premiums at an interest rate of 7.79 % and 5.48 % respectively, with an aggregate principal amount outstanding of approximately $ 670,000 and $ 764,000 as of December 31, 2023 and 2022, respectively. The amount outstanding in 2023 could be substantially offset by the cancellation of the related insurance coverage which is classified in prepaid insurance. These notes are payable in ten monthly installments with maturity dates of October 1, 2024 and October 1, 2023 , respectively. The carrying value of the Company’s insurance promissory note approximates fair value at December 31, 2023 and 2022, due to the short-term nature of the insurance note and are classified as Level 2 within the fair value hierarchy. Operating Leases The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease. The Company’s principal facility, including the CLIA laboratory used by Aspira Labs , is located in Austin, Texas, and administrative offices are located in Shelton, Connecticut and Palo Alto, California. In July 2023, the Company extended the Austin, Texas lease for an additional 37 months. The Company’s renewed lease expires on February 28, 2027 , with the option to extend the lease for an additional three years . Prior to the renewal, the Company’s Texas lease had a term of 12 months, and the Company has elected the policy of not recording leases on the balance sheet when the leases have terms of 12 months or less. Through June 30, 2023, the Company recognized the lease payments in profit and loss on a straight-line basis over the term of the lease, and variable lease payments in the period in which the obligation for the payments was incurred. Variable lease costs represent our share of the landlord’s operating expenses. Beginning in the third quarter of 2023, the Company added the extended Austin, Texas lease to its balance sheet as a right-of-use asset. The Company is not reasonably certain that it will exercise the three year renewal option beginning on March 1, 2027. In October 2015, the Company entered into a lease agreement for a facility in Trumbull, Connecticut, which was renewed in September 2020. On May 30, 2023, the Company entered into an agreement with the owner of its Trumbull, Connecticut offices to move to a more economical location in Shelton, Connecticut. The new lease in Shelton, Connecticut cancelled and replaced the Trumbull, Connecticut office lease. The new lease term is for five years, and its commencement date was October 1, 2023. Continuation of the lease would be on a month-to-month basis. In January 2023, the Company entered into a new sublease agreement for an administrative facility in Palo Alto, California. The Company’s sublease term commenced in April 2023 and expires on May 31, 2024 , with no option for renewal with the sublessor . The sublessor, Invitae, filed for bankruptcy on February 15, 2024. There will be no impact to the Company as a result of this bankruptcy filing. The expense associated with these operating leases for the years ended December 31, 2023 and 2022 is shown in the table below (in thousands ). Included in the amounts below are $ 58,000 and $ 32,000 of short term lease expenses related to rent and variable costs, respectively, for one lease during 2023 prior to its treatment as a right-of-use asset and $ 114,000 and $ 54,000 related to rent and variable costs, respectively, during 2022 .  Year Ended December 31, Lease Cost Classification 2023 2022 Operating rent expense Cost of revenue $ 83 $ 79 Research and development 63 27 Sales and marketing 11 37 General and administrative 115 66 Variable rent expense Cost of revenue $ 52 $ 39 Research and development 14 22 Sales and marketing 9 34 General and administrative 74 67 Based on the Company’s leases as of December 31, 2023, the table below sets forth the approximate future lease payments related to operating leases with initial terms of one year or more (in thousands). Year Payments 2024 $ 194 2025 167 2026 171 2027 84 2028 52 Total Operating Lease Payments 668 Less: Imputed Interest ( 82 ) Present Value of Lease Liabilities 586 Less: Operating Lease Liability, current portion ( 159 ) Operating Lease Liability, non-current portion $ 427 Supplemental disclosure of cash flow information related to leases for the years ended December 31, 2023 and 2022 is shown in the table below (in thousands). Year Ended December 31, 2023 2022 Cash paid for amounts included in measurement of lease liabilities: Operating cash outflows relating to operating leases $ 459 $ 362 Weighted-average remaining lease term (in years) 3.6 3.5 Weighted-average discount rate 7.30 % 9.30 % Non-cancelable Royalty Obligations and Other Commitments The Company is a party to an amended research collaboration agreement with The Johns Hopkins University School of Medicine under which the Company licenses certain of its intellectual property directed at the discovery and validation of biomarkers in human subjects, including but not limited to clinical application of biomarkers in the understanding, diagnosis and management of human diseas e. Under the terms of the amended research collaboration agreement, Aspira is required to pay the greater of 4 % royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $ 57,500 . Royalty expense for the years ended December 31, 2023 and 2022 totaled $ 324,000 and $ 318,000 , respectively, as recorded in cost of revenue in the consolidated statements of operations. Commercial Reorganization During the first quarter of 2022, the Company executed a commercial reorganization resulting in the separation of a number of employees. The organizational changes resulted in the recording within the consolidated statement of operations in sales and marketing, research and development and general and administrative expenses of one-time severance, separation, and settlement charges of approximately $ 1,284,000 . These amounts have been partially offset by insurance reimbursement of $ 523,000 . All charges were settled as of December 31, 2022. Business Agreements In August 2022, the Company entered into a sponsored research agreement with Harvard’s Dana-Farber Cancer Institute, Brigham & Women’s Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs and proteins. The results of this collaboration will be advanced, co-developed technology to guide medical and clinical management of women presenting with symptoms of endometriosis. This collaboration is expected to accelerate the development and commercialization of future endometriosis products, such as EndoCheck. The contract requires payments to be made upon the achievement of certain milestones. Under the terms of and as further described in the agreement, payments of approximately $ 1,252,000 have or will become due from the Company to the counterparties upon successful completion of certain deliverables in 2022 and 2023 as follows: 68 % was paid in 2022, 15 % was paid in 2023, and the remaining 17 % will become payable upon completion of certain deliverables estimated to occur in the first half of 2024. During the year ended December 31, 2023, approximately $ 215,000 has been recorded as research and development expense in the Company’s consolidated financial statement of operations for the project. During the year ended December 31, 2022, approximately $ 868,000 , was recorded as research and development expense in the Company’s consolidated financial statement of operations for the project. From the inception of the Dana-Faber, Brigham, Lodz Research Agreement through December 31, 2023, research and development expenses in the cumulative amount of $ 1,083,000 have been recorded. From the inception of the Dana-Faber, Brigham, Lodz Research Agreement through December 31, 2023 , the Company made payments totaling $ 1,040,000 . Additional payments of $ 212,000 are due to the collaboration partners in 2024 under the terms of the agreement. On March 20, 2023, the Company entered into a licensing agreement (“Dana-Faber, Brigham, Lodz License Agreement”) with Harvard’s Dana-Farber Cancer Institute, Brigham & Women’s Hospital, and Medical University of Lodz under which the Company will license certain of its intellectual property to be used in the Company’s OvaSuite product portfolio. Under the Dana-Faber, Brigham, Lodz License Agreement, the Company paid an initial license fee of $ 75,000 , which was recorded as research and development expense on the Company's consolidated financial statement of operations, and then will pay a license maintenance fee of $ 50,000 on each anniversary of the date of the Dana-Faber, Brigham, Lodz License Agreement. The Dana-Faber, Brigham, Lodz License Agreement also requires non-refundable royalty payments of up to $ 1,350,000 based on certain regulatory approvals and commercialization milestones and further royalty payments based on the net sales of the Company’s products included under the Dana-Faber, Brigham, Lodz License Agreement. No milestones have been reached as of December 31, 2023. Contingent Liabilities From time to time, the Company is involved in legal proceedings and regulatory proceedings arising from operations. The Company establishes reserves for specific liabilities in connection with legal actions that management deems to be probable and estimable. The Company is not currently a party to any proceeding, the adverse outcome of which would have a material adverse effect on the Company’s financial position or results of operations.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2023
Common Stock [Abstract]
Common Stock	NOTE 7: Common Stock Additional Shares Authorized On February 6, 2023, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of the Company’s common stock from 150,000,000 shares to 200,000,000 shares. 2022 Public Offering On August 22, 2022, the Company entered into an underwriting agreement (the “2022 Underwriting Agreement”) with William Blair & Company, L.L.C., as the sole underwriter (the “2022 Underwriter”). Pursuant to the 2022 Underwriting Agreement, the Company agreed to issue and sell, in an underwritten public offering (the “2022 Offering”), 800,000 shares of the Company’s common stock, par value $ 0.001 per share (“Common Stock”) and warrants to purchase up to 799,985 shares of Common Stock (the “Warrants”). Each share of Common Stock was sold together with one Warrant to purchase one share of Common Stock, at a price to the public of $ 11.25 per share and related Warrant. The Warrants were issued pursuant to a common stock purchase warrant (the “Form of Warrant”). Each Warrant has an initial exercise price equal to $ 13.20 per share of Common Stock and are exercisable for five years from the date of issuance. The exercise price and the number of shares of Common Stock issuable upon exercise of the Warrants are subject to adjustment in the event of certain subdivisions and combinations, including by any stock split or reverse stock split, stock dividend, recapitalization or otherwise. The exercise of the Warrants may be limited in certain circumstances if, after giving effect to such exercise, the holder or any of its affiliates would beneficially own (as determined in accordance with the terms of the Warrants) more than 4.99 % (or, at the election of the holder, 9.99 %) of the outstanding Common Stock immediately after giving effect to the exercise. There is no established trading market available for the Warrants on any securities exchange or nationally recognized trading system. The Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815-40, including whether the warrants are indexed to the Company’s own stock and whether the events where holders of the warrants could potentially require net cash settlement are within the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. As further described in the Form of Warrant, if the Company consummates any merger, consolidation, sale or other reorganization event, including the sale of all or substantially all of the Company’s assets, in which its common stock is converted into or exchanged for securities, cash or other property (“Fundamental Transaction”), then the Company shall pay at the holder’s option, exercisable at any time commencing on the occurrence or the consummation of the Fundamental Transaction (or, if later, the date of public announcement) and continuing up to 30 days, an amount of cash equal to the value of the remaining unexercised portion of the Warrant as determined in accordance with the Black-Scholes option pricing model on the date of such Fundamental Transaction provided; however, that if the Fundamental Transaction is not within the Company’s control, including not approved by the Board of Directors, the holder of the Warrant shall only be entitled to receive the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the Warrant, that is being offered and paid to the holder of the Common Stock of the Company in connection with the Fundamental Transaction. The Black-Scholes option pricing model, as defined in the Form of Warrant, includes as an input, the highest volume weighted average price (“VWAP”) for a period of one trading day preceding the consummation or announcement of a Fundamental Transaction up to 30 days after a Fundamental Transaction. The Company has determined that an adjustment based on this input is not limited to the effect that is attributable to the Fundamental Transaction and therefore causes the Warrants to fail the indexation guidance under ASC 815-40. As a result, the Company has determined that the Warrants must be recorded as derivative liabilities upon issuance and marked to market each reporting period in the Company’s consolidated statement of operations until their exercise or expiration. The Company’s Warrants are classified as a long-term Warrant liability on the Company’s balance sheet. The fair values of the Warrants as of December 31, 2023 and December 31, 2022 were $ 1,651,000 and $ 2,280,000 , respectively. The fair value of the Warrants was estimated using Black-Scholes pricing model based on the following assumptions: December 31, 2023 December 31, 2022 Dividend yield - % - % Volatility 105.1 % 96.8 % Risk-free interest rate 3.93 % 3.99 % Expected lives (years) 3.64 4.64 Weighted average fair value $ 2.064 $ 2.850 The fair value of the Warrants was deemed to be derivative instruments due to certain contingent put feature, was determined using the Black-Scholes option pricing model, deemed to be an appropriate model due to the terms of the Warrants issued, including a fixed term and exercise price. The fair value of Warrants was affected by changes in inputs to the Black-Scholes option pricing model including the Company’s stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. This model uses Level 2 inputs, including stock price volatility, in the fair value hierarchy established by ASC 820 Fair Value Measurement. The 2022 Offering resulted in net proceeds to the Company of approximately $ 7,675,000 , after deducting underwriting discounts and offering expenses of $ 1,325,000 . Offering costs were allocated between expense and equity based on the percentage of the Warrant fair value of $ 3,984,000 and the total gross proceeds of $ 9,000,000 . $ 574,000 of offering costs were allocated to the Warrants and were expensed immediately and recorded as other income (expense) in the consolidated statement of operations for the year ended December 31, 2022, resulting in a net impact to the Company’s equity of $ 751,000 . 2023 At the Market Offering On February 10, 2023, the Company entered into a Controlled Equity Offering Sales Agreement (the “Cantor Sales Agreement”), with Cantor Fitzgerald & Co. (“Cantor”) as agent, pursuant to which it may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $ 0.001 per share, having an aggregate offering price of up to $ 12.5 million (the “Placement Shares”). Under the Cantor Sales Agreement, Cantor may sell the Placement Shares by any method permitted by law and deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on the Nasdaq Capital Market, on any other existing trading market for our common stock or to or through a market maker or in privately negotiated transactions. Cantor receives a Placement Fee of 3% for each completed sale of Placement Shares under the Cantor Sales Agreement. The Company is not obligated to make any sales of the Placement Shares under the Cantor Sales Agreement. The offering of the Placement Shares pursuant to the Cantor Sales Agreement will terminate upon the earlier of (a) the sale of all of the Placement Shares subject to the Cantor Sales Agreement or (b) the termination of the Cantor Sales Agreement by Cantor or the Company, as permitted therein. As of December 31 , 2023, and December 31, 2022, the Company had $ 0 and $ 150,000 , respectively, of deferred transaction-related offering costs recorded in other assets in the Company’s consolidated balance sheet. $ 7,000 was recorded as an offset to additional paid-in-capital representing transaction-related offering costs related to the Cantor Sales Agreement. The remaining $ 143,000 was recorded as general and administrative expense on the Company's consolidated financial statement of operations. During the year ended December 31, 2023, the Company sold 35,552 shares of the Placement Shares, for gross proceeds of approximately $ 211,000 . For the year ended December 31, 2023, the Company recorded $ 134,000 as an offset to additional paid-in capital representing transaction-related offering costs of the Placement Shares. In connection with a follow-on equity offering on July 24, 2023, the Company delivered written notice to Cantor on July 19, 2023 that it was suspending the prospectus supplement, dated February 10, 2023, related to the Company’s common stock issuable under the Cantor Sales Agreement. The Company will not make any sales of common stock pursuant to the Cantor Sales Agreement unless and until a new prospectus supplement is filed with the SEC. The Cantor Sales Agreement remains in full force and effect during the suspension. 2023 Equity Line of Credit On March 28, 2023, the Company entered into a purchase agreement (the “LPC Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”) and a registration rights agreement (the “LPC Registration Rights Agreement”), pursuant to which the Company has the right, in its sole discretion, to sell to Lincoln Park shares of the Company’s common stock, par value $ 0.001 per share (the “Common Stock”), having an aggregate value of up to $ 10,000,000 (the “Purchase Shares”), subject to certain limitations and conditions set forth in the LPC Purchase Agreement. The Company will control the timing and amount of any sales of Purchase Shares to Lincoln Park pursuant to the LPC Purchase Agreement. Under the LPC Purchase Agreement, on any business day after March 28, 2023 selected by the Company over the 36 -month term of the LPC Purchase Agreement (each, a “Purchase Date”), the Company may direct Lincoln Park to purchase up to 6,667 shares of Common Stock on such Purchase Date (a “Regular Purchase”); provided, however, that (i) a Regular Purchase may be increased to up to 13,333 shares, if the closing sale price per share of the Common Stock on The Nasdaq Capital Market is not below $ 7.50 on the applicable Purchase Date; (ii) a Regular Purchase may be increased to up to 16,666 shares, if the closing sale price per share of the Common Stock on The Nasdaq Capital Market is not below $ 11.25 on the applicable Purchase Date; and (iii) a Regular Purchase may be increased to up to 20,000 shares, if the closing sale price per share of the Common Stock on The Nasdaq Capital Market is not below $ 15.00 on the applicable Purchase Date. All terms of the LPC Purchase Agreement have been adjusted for the Reverse Stock Split. In any case, Lincoln Park’s maximum obligation under any single Regular Purchase will not exceed $ 1,000,000 . The above-referenced share amount limitations and closing sale price thresholds are subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction as provided in the LPC Purchase Agreement. The purchase price per share for each such Regular Purchase will be equal to the lesser of: 1. the lowest sale price for the Common Stock on The Nasdaq Capital Market on the date of sale; and 2. the average of the three lowest closing sale prices for the Common Stock on The Nasdaq Capital Market during the 10 consecutive business days ending on the business day immediately preceding the purchase date. The Company also has the right to direct Lincoln Park, on any business day on which the Company has properly submitted a Regular Purchase notice for the maximum amount the Company is then permitted to sell to Lincoln Park in such Regular Purchase, to purchase an additional amount of the Common Stock (an “Accelerated Purchase”) of a dditional shares based on criteria established in the LPC Purchase Agreement. An Accelerated Purchase, which is at the Company’s sole discretion, may be subject to additional requirements and discounts if certain conditions are met as defined in the LPC Purchase Agreement. During the year ended December 31, 2023, the Company sold 360,943 shares under the LPC Purchase Agreement for gross proceeds of approximately $ 1,177,000 . The Company incurred approximately $ 329,000 of costs related to the execution of the LPC Purchase Agreement, all of which are reflected in the Company’s consolidated financial statements. Of the total costs incurred, approximately $ 258,000 was paid in common stock to Lincoln Park for a commitment fee and $ 30,000 was paid for Lincoln Park expenses. These transaction costs were included in other expense in the Company’s statement of operations. Approximately $ 41,000 was incurred for legal fees during the year ended December 31, 2023 and were included in general and administrative expenses on the Company’s statement of operations. 2023 Registered Direct Offering On July 20, 2023, the Company entered into a securities purchase agreement (the “2023 Direct Offering Agreement”), with several investors relating to the issuance and sale of 1,694,820 shares of its common stock, par value $ 0.001 per share (the “2023 Direct Offering”). Pursuant to the 2023 Direct Offering Agreement, the Company issued 1,650,473 shares of common stock to certain investors at an offering price of $ 2.75 per share, and 44,347 shares of common stock to its directors and executive officers at an offering price of $ 3.98 per share, which was the consolidated closing bid price of the Company’s common stock on The Nasdaq Capital Market on July 19, 2023. The aggregate gross proceeds to the Company from the 2023 Direct Offering were approximately $ 4.7 million, before deducting placement agent fees and other estimated expenses of $ 597,000 payable by the Company. The Company engaged Alliance Global Partners (“AGP”) to act as sole placement agent in the 2023 Direct Offering. The Company paid the placement agent a cash fee equal to 7.0 % of the aggregate gross proceeds generated from the 2023 Direct Offering, except that, with respect to proceeds from the sale of 182,447 shares of common stock to certain investors, including directors and executive officers of the Company, the placement agent’s cash fee was 3.5 %. The Company also reimbursed the placement agent for its accountable offering-related legal expenses of $ 75,000 and a non-accountable expense allowance of $ 30,000 . Warrants Warrants outstanding as of December 31, 2023 and 2022 were as follows: Exercise Price Number of Shares Outstanding under Warrant Issuance Date Expiration Date per Share December 31, 2023 December 31, 2022 August 25, 2022 August 25, 2027 $ 13.20 799,985 799,985 799,985 799,985 As discussed in Note 12, effective upon the closing of a follow-on equity offering, the Company also amended certain of the existing warrants to purchase up to an aggregate of 366,664 shares at an exercise price of $ 13.20 per share and a termination date of August 25, 2027, so that the amended warrants will have a reduced exercise price of $ 4.13 per share and a new termination date of January 26, 2029. The other terms of the amended warrants will remain unchanged.

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2023
Loss Per Share [Abstract]
Loss Per Share	NOTE 8: Loss Per Share The reconciliation of the numerators and denominators of basic and diluted loss per share for the years ended December 31, 2023 and 2022 was as follows: Year Ended December 31, 2023 2022 Numerator: Net Loss $ ( 16,690 ) $ ( 29,885 ) Denominator: Shares used in computing net loss per share, basic and diluted 9,233,306 7,769,109 Net loss per share, basic and diluted $ ( 1.81 ) $ ( 3.85 ) Due to net losses for the years ended December 31, 2023 and 2022, diluted loss per share is calculated using the weighted average number of common shares outstanding and excludes the effects of potential shares of common stock that are antidilutive. The potential shares of common stock that have been excluded from the diluted loss per share calculation above for the years ended December 31, 2023 and 2022 were as follows: Year Ended December 31, 2023 2022 Stock options 759,922 655,139 Restricted stock units 59,463 - Warrants 799,985 799,985 Potential common shares 1,619,370 1,455,124

Employee Share Based Compensati

Employee Share Based Compensation And Benefit Plans	12 Months Ended
	Dec. 31, 2023
Employee Share Based Compensation And Benefit Plans [Abstract]
Employee Share Based Compensation And Benefit Plans	NOTE 9: Employee SHARE BASED COMPENSATION AND Benefit Plans 2010 Stock Incentive Plan The Company’s employees, directors, and consultants were eligible to receive awards under the Vermillion, Inc. Second Amended and Restated 2010 Stock Incentive Plan, which was replaced by the 2019 Plan (as defined below) with respect to future equity grants. As of December 31, 2023, there were no shares of Aspira common stock available for future grants under the 2010 Plan. As of December 31, 2023, a total of 245,154 shares of Aspira common stock were reserved for issuance with respect to outstanding stock options. 2019 Stock Incentive Plan At the Company’s 2019 annual meeting of stockholders, the Company’s stockholders approved the Vermillion, Inc. 2019 Stock Incentive Plan, which was later amended to the Aspira Women’s Health Inc. (the “2019 Plan”). The purposes of the 2019 Plan are (i) to align the interests of the Company’s stockholders and recipients of awards under the 2019 Plan by increasing the proprietary interest of such recipients in the Company’s growth and success; (ii) to advance the interests of the Company by attracting and retaining non-employee directors, officers, other employees, consultants, independent contractors and agents; and (iii) to motivate such persons to act in the long-term best interests of the Company and its stockholders. The 2019 Plan allows the Company to grant stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to participants. Subject to the terms and conditions of the 2019 Plan, the initial number of shares authorized for grants under the 2019 Plan is 699,485 . In May 2023, the Company’s stockholders approved an increase of 333,333 to the number of shares available for issuance under the 2019 Plan for a total of 1,032,818 . To the extent an equity award granted under the 2019 Plan expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares of common stock subject to such award will become available for future grant under the 2019 Plan. As of December 31, 2023, there were 165,861 shares of Aspira common stock available for future grants under the 2019 Plan. As of December 31, 2023, there were 514,768 shares of Aspira common stock subject to outstanding stock options and there were 59,463 outstanding restricted stock units. The activity related to shares available for grant under the 2010 Plan and the 2019 Plan for the years ended December 31, 2023 and 2022 was as follows: 2010 Stock Option Plan 2019 Stock Option Plan Total Shares available at December 31, 2021 - 248,613 248,613 Options forfeited 2,650 198,625 201,275 Options granted - ( 174,175 ) ( 174,175 ) Restricted stock units forfeited - 346 346 Restricted stock units granted - ( 29,223 ) ( 29,223 ) Shares expired ( 2,650 ) ( 5,754 ) ( 8,404 ) Shares available at December 31, 2022 - 238,432 238,432 Shares added to the plan - 333,333 333,333 Options forfeited 41,950 250,859 292,809 Options granted - ( 397,503 ) ( 397,503 ) Restricted stock units forfeited - - - Restricted stock units granted - ( 259,161 ) ( 259,161 ) Shares expired ( 41,950 ) ( 99 ) ( 42,049 ) Shares available at December 31, 2023 - 165,861 165,861 The stock option activity under the 2010 Plan and the 2019 Plan for the years ended December 31, 2023 and 2022 was as follows: Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term Options outstanding at December 31, 2021 683,861 $ 44.40 $ 3,797,181 7.44 Granted 174,175 14.17 Exercised ( 1,533 ) 8.13 Forfeited ( 201,275 ) 68.12 Options outstanding at December 31, 2022 655,228 $ 29.25 $ - 6.06 Granted 397,503 6.57 Exercised - - Forfeited ( 292,809 ) 28.90 Options outstanding at December 31, 2023 759,922 $ 17.48 $ 113,929 5.37 Shares exercisable: December 31, 2023 452,606 $ 22.57 $ 33,073 3.03 Shares expected to vest: December 31, 2023 201,328 $ 10.31 $ 41,992 8.45 The total intrinsic value of options exercised during the years ended December 31, 2023 and 2022 was $ 0 and $ 5,000 respectively. The total fair value of vested options as of December 31, 2023 and 2022 was $ 6,073,000 and $ 5,982,000 , respectively. Stock-based Compensation Stock-based Compensation Expense The Company records stock-based compensation net of estimated forfeitures. The assumptions used to calculate the fair value of options granted under the 2010 Plan and the 2019 Plan that were incorporated in the Black-Scholes pricing model for the years ended December 31, 2023 and 2022 were as follows: December 31, 2023 December 31, 2022 Dividend yield - % - % Volatility 138.3 % 92.7 % Risk-free interest rate 4.45 % 2.45 % Expected lives (years) 2.00 2.00 Weighted average fair value $ 4.160 $ 7.350 The non-cash stock-based compensation expense included in cost of revenue and operating expenses by functional area for the years ended December 31, 2023 and 2022 was as follows: Year Ended December 31, (in thousands) 2023 2022 Cost of revenue $ 33 $ 76 Research and development 325 177 Sales and marketing 47 354 General and administrative 1,319 1,807 Total $ 1,724 $ 2,414 As of December 31, 2023, total unrecognized compensation cost related to unvested stock option awards was approximately $ 677,000 , and the related weighted average period over which it is expected to be recognized was 1.81 years. As of December 31, 2023, there was $ 104,000 in unrecognized compensation costs related to restricted stock units, and the related weighted average period over which it is expected to be recognized is 0.50 years. 401(k) Plan The Company’s 401(k) Plan allows eligible employees to defer up to an annual limit of the lesser of 90.0 % of eligible compensation or a maximum contribution amount subject to the Internal Revenue Service annual contribution limit. The Company is not required to make Company contributions under the 401(k) Plan. During the years ended December 31, 2023 and 2022, the Company did no t make Company contributions to the 401(k) Plan.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
Income Taxes	NOTE 10: Income Taxes There was no current income tax expense or benefit for the years ended December 31, 2023 or 2022 because of net losses during those years. These net losses were generated from domestic operations. Loss from continuing operations before income taxes for the years ended December 31, 2023 and 2022 were $ 16.7 million and $ 29.9 million, respectively. Based on the available objective evidence, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets at December 31, 2023 and 2022. Therefore, there was no deferred income tax expense or benefit for the years ended December 31, 2023 or 2022. There is no portion of the valuation allowance for deferred tax assets for which subsequently recognized tax benefits will be credited directly to contributed capital. The components of net deferred tax assets (liabilities) at December 31, 2023 and 2022 were as follows: Year Ended December 31, (in thousands) 2023 2022 Deferred tax assets: Net operating losses $ 52,540 $ 44,509 Capitalized research expenses 3,432 3,686 Fixed asset depreciation 487 678 Other 697 804 ASC 842 Right of Use Liability 137 - Total deferred tax assets 57,293 49,677 Valuation allowance ( 57,170 ) ( 49,677 ) Deferred tax assets $ 123 $ - Deferred tax liabilities: ASC 842 Right of Use Asset $ ( 123 ) $ - Deferred tax liabilities $ ( 123 ) $ - Net deferred tax asset $ - $ - The reconciliation of the statutory federal income tax rate to the Company’s effective tax rate for the years ended December 31, 2023 and 2022 was as follows: Year Ended December 31, 2023 2022 Tax at federal statutory rate 21 % 21 % State tax, net of federal benefit - 5 Change in valuation allowance ( 17 ) ( 26 ) Change in warrant valuation 1 1 Net operating loss reduction due to Section 382 limitation ( 1 ) - Permanent items ( 1 ) ( 1 ) Deferred Adjustments, Return to Provision ( 3 ) - Effective income tax rate - % - % The Company's ability to use its net operating loss and credit carryforwards to offset future taxable income is restricted due to ownership change limitations that have occurred in the past, as required by Section 382 of the Internal Revenue Code of 1986, as amended (“Section 382”), as well as similar state provisions. Net operating losses which are limited from offsetting any future taxable income under Section 382 are not included in the gross deferred tax assets presented above. The Company's pre-2018 federal NOLs of $ 67 million, which are not limited from offsetting future taxable income under Section 382, will expire in varying amounts from 2024 through 2037 , if not utilized, and can offset 100% of future taxable income for regular tax purposes. The Company also has pre-2018 federal NOLs of approximately $ 31 million that will expire if not utilized within 20 years of being generated that are limited in offsetting future taxable income under Section 382. A portion may still potentially be utilized before they expire, but the portion which will not be able to be utilized prior to expiration has been removed from gross deferred tax assets. The Company’s federal NOLs of $ 116 million arising on or after January 1, 2018, can generally be carried forward indefinitely but such federal NOL carryforwards are permitted to be used in any table year to offset up to 80% of future taxable income annually. State NOLs will expire in varying amounts from 2024 through 2043 if not utilized. The Company’s ability to use its NOLs during this period will be dependent on the Company’s ability to generate taxable income, and portions of the Company’s NOLs could expire before the Company generates sufficient taxable income . The valuation allowance was $ 57.2 million and $ 49.7 million at December 31, 2023 and 2022, respectively. The increase of approximately $ 7.5 million between 2022 and 2023 is primarily due to adjustments to the domestic deferred tax assets related to net operating losses. The Company files income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. The Company has not been audited by the Internal Revenue Service or any state income or franchise tax agency. As of December 31, 2023, the Company's federal returns for the years ended 2020 through the current period and most state returns for the years ended 2019 through the current period are still open to examination. In addition, all of the net operating losses and research and development credits generated in years earlier than 2020 and 2019, respectively, are still subject to Internal Revenue Service audit. The federal and California tax returns for the year ended December 31, 2022 reflect research and development carryforwards of $ 4.4 million and $ 5.9 million, respectively. For the year ended December 31, 2023, the Company anticipates claiming additional research and development credits of $ 0.3 million on its federal tax return and $ 0.2 million on its California tax return. As of December 31, 2023, the Company's gross unrecognized tax benefits are approximately $10.7 million which are attributable to research and development credits. A reconciliation of the change in the Company's unrecognized tax benefits is as follows: (in thousands) Federal Tax State Tax Total Balance at December 31, 2021 $ 4,937 $ 5,644 $ 10,581 Return to provision true up - - - Increase in tax position during 2022 223 212 435 Decrease due to expirations during 2022 ( 785 ) - ( 785 ) Balance at December 31, 2022 $ 4,375 $ 5,856 $ 10,231 Return to provision true up - - - Increase in tax position during 2023 282 211 493 Decrease due to expirations during 2023 - - - Balance at December 31, 2023 $ 4,657 $ 6,067 $ 10,724 The increase for the year ended December 31, 2023 is related to positions taken in that year. If the $ 10.7 million of unrecognized income tax benefit is recognized, approximately $ 10.7 million would impact the effective tax rate in the period in which each of the benefits is recognized. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the consolidated statement of operations and comprehensive loss. The Company has no t recorded any interest or penalties as a result of uncertain tax positions as of December 31, 2023 and 2022. Accrued interest and penalties would be included within the related liability in the consolidated balance sheet.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 11: Related Party Transactions None.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	NOTE 12: SUBSEQUENT EVENTS On January 24, 2024, the Company entered into a securities purchase agreement (the “2024 Direct Offering Agreement”), with several investors relating to the issuance and sale of 1,371,000 shares of its common stock, par value $ 0.001 per share, and pre-funded warrants to purchase 200,000 shares of Common Stock (the “Pre-Funded Warrants”), in a registered direct offering, together with accompanying warrants to purchase 1,571,000 shares of Common Stock (the “Purchase Warrants”, and together with the Pre-Funded Warrants, the “Warrants”) in a concurrent private placement (the “Concurrent Private Offering” and together with the registered direct offering, the “2024 Direct Offering”). Pursuant to the 2024 Direct Offering Agreement, the Company issued 1,368,600 shares of common stock to certain investors at an offering price of $ 3.50 per share, and 2,400 shares of common stock to its Chief Executive Officer, Nicole Sandford, at an offering price of $ 4.2555 per share, which was the consolidated closing bid price of our common stock on The Nasdaq Capital Market on January 24, 2024 of $ 4.13 per share plus $ 0.125 per Purchase Warrant. The purchase price of each Pre-Funded Warrant is equal to the combined purchase price at which a share of Common Stock and the accompanying Purchase Warrant is sold in this 2024 Direct Offering, minus $ 0.0001 . The gross proceeds to the Company from the 2024 Direct Offering were approximately $ 5.5 million, before deducting placement agent fees and other estimated expenses of $ 941,000 payable by the Company. The 2024 Direct Offering closed on January 26, 2024. The Pre-Funded Warrants will be exercisable at any time after the date of issuance and will have an exercise price of $ 0.0001 per share. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99 % of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage to a percentage not in excess of 9.99 % by providing at least 61 days’ prior notice to the Company. The Purchase Warrants will have an exercise price of $ 4.13 per share and will be exercisable beginning six months after issuance and will expire 5 years from the initial exercise date. The Company engaged AGP to act as sole placement agent in the 2024 Direct Offering. The Company paid the placement agent a cash fee equal to 7.0 % of the aggregate gross proceeds generated from the 2024 Direct Offering, except that, with respect to proceeds raised in this 2024 Direct Offering from certain designated persons, AGP’s cash fee is reduced to 3.5 % of such proceeds, and to reimburse certain fees and expenses of the placement agent in connection with the 2024 Direct Offering . The Company also reimbursed the placement agent for its accountable offering-related legal expenses of $ 75,000 and a non-accountable expense allowance of $ 30,000 . Effective upon the closing of the 2024 Direct Offering, the Company also amended certain existing warrants to purchase up to an aggregate of 366,664 shares at an exercise price of $ 13.20 per share and a termination date of August 25, 2027, so that the amended warrants will have a reduced exercise price of $ 4.13 per share and a new termination date of January 26, 2029. The other terms of the amended warrants will remain unchanged.

Basis Of Presentation And Sum_2

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies (Policy)	12 Months Ended
	Dec. 31, 2023
Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies [Abstract]
Organization And Basis of Presentation	Organization and Basis of Presentation Aspira Women’s Health Inc., formerly known as Vermillion, Inc. (“Aspira,” and together with its wholly-owned subsidiaries, the “Company ”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company currently markets and sells the following products and related services: (1) the Ova1Plus workflow, which uses Ova1, a qualitative serum test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical and radiological evaluation does not indicate malignancy, as the primary test and Overa, a second-generation biomarker test intended to maintain Ova1’s high sensitivity while improving specificity, as a reflex for Ova1 intermediate range results, leveraging the strengths of Ova1’s MIA sensitivity and Overa’s (MIA2G) specificity to reduce incorrectly elevated results; and (2) OvaWatch, an LDT intended to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. Overa is currently not offered except as a reflex test performed as part of the Ova1Plus workflow. Collectively, these tests are referred to and marketed as OvaSuite. For the year ended December 31, 2023, the Company’s product and related revenue was limited to these products, and Aspira GenetiX, which was discontinued in the third quarter of 2022. The Company’s products are distributed through its own national sales force, through its proprietary decentralized testing platform and cloud service marketed as Aspira Synergy, and through marketing and distribution agreements with BioReference Health, LLC and ARUP Laboratories.
Going Concern	Going Concern The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $ 518.3 million and working capital of $ 0.2 million as of December 31, 2023. For the year ended December 31, 2023, the Company incurred a net loss of $ 16.7 million and used cash in operations of $ 15.9 million. The Company also expects to incur a net loss and negative cash flows from operations for 2024. In order to continue our operations as currently planned through 2024 and beyond, the Company will need to raise additional capital. The Company expects to take further action to protect its liquidity position. Such actions may include, but are not limited to:  Raising capital through an equity offering either in the public markets or via a private placement offering (to the extent that the Company raises additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. However, no assurance can be given that capital will be available on acceptable terms, or at all) ;  Securing debt, however, no assurance can be given that debt will be available on acceptable terms or at all;  Reducing executive bonuses or replacing cash compensation with equity grants;  Reducing professional services and consulting fees and eliminating non-critical projects;  Reducing travel and entertainment expenses; and  Reducing, eliminating or deferring discretionary marketing programs. The Company also has outstanding warrants to purchase shares of its common stock that may be exercised; although there can be no assurance that the warrants will be exercised. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. Management expects cash from product sales and licensing to be the Company’s only material, recurring source of cash in 2024. Given the above conditions, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are filed. The consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. On June 1, 2022, the Company received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market stating that, for the preceding 30 consecutive business days, the closing bid price for Aspira common stock was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). On November 29, 2022, the Company was granted an additional 180-calendar day compliance period, or until May 29, 2023, to regain compliance with the minimum bid price requirement. On May 26, 2023, the Company received notice from Nasdaq that it had regained compliance. On July 11, 2023, the Company received a second deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that, for the 30 consecutive business days prior to the date of the deficiency letter, the Company’s Market Value of Listed Securities was below the minimum of $ 35 million requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq provided the Company with 180 calendar days, or until January 8, 2024, to regain compliance with the MVLS Requirement. On September 12, 2023, the Company received notice from Nasdaq that it had regained compliance. T here is no assurance that the Company will maintain compliance with the MVLS Requirement or any of the other Nasdaq continued listing requirements.
Basis Of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated in consolidation
Use Of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company’s equity awards, warrants, income taxes and contingent liabilities. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.
Cash And Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes. Highly liquid investments that are considered cash equivalents include money market funds.
Restricted Cash	Restricted Cash Restricted cash consists of a security deposit for a credit card financing arrangement. The restriction on the cash will be removed when the Company closes its credit card account.
Fair Value Measurement	Fair Value Measurement Accounting Standards Codification (“ASC”) Topic 820, Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. Financial instruments of the Company consist primarily of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, debt and warrant liability. Cash and cash equivalents, restricted cash, accounts receivable, and accounts payable are considered Level 1 due to their short-term nature and their market interest rates. Warrant liability is considered Level 2 and is recorded at fair value at the end of each reporting period.
Concentration Of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of $250,000 but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities.
Accounts Receivable	Accounts Receivable Virtually all accounts receivable are derived from sales made to customers located in North America. The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The Company maintains an allowance for credit losses based upon the expected collectability of accounts receivable, such as the historical collection cycle. Amounts are written off against the allowances for credit losses when the Company determines that a customer account is not collectable. We believe our exposure to concentrations of credit risk is limited due to the diversity of our payer base.
Inventory	Inventory The Company has inventory consisting primarily of kit inventory for specimen delivery as well as reagents used for specimen testing and miscellaneous inventory such as pipettes, gloves and other non-reagent items. At each reporting period the Company reviews its inventories for obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realized value, which is primarily related to kit inventory when kits expire. Inventory is valued at cost using the first-in-first-out method.
Property And Equipment	Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years . Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.
Revenue Recognition	Revenue Recognition Product Revenue – OvaSuite: The Company recognizes product revenue in accordance with the provisions of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Product revenue is recognized upon completion of the OvaSuite test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year. The effect of any change made to an estimated input component and, therefore revenue recognized, would be recorded as a change in estimate at the time of the change. The Company also reviews its patient account population and determines an appropriate distribution of patient accounts by payer (i.e., Medicare, patient pay, other third-party payer, etc.) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. During the years ended December 31, 2023 and 2022, there were no material adjustments to estimates of variable consideration to derecognize revenue for services provided in a prior period. There were no impairment losses on accounts receivable recorded during the years ended December 31, 2023 and 2022. Genetics Revenue – Aspira GenetiX: Under ASC 606, the Company’s genetics revenue was recognized upon completion of the Aspira GenetiX test and delivery of results to the physician based on estimates of amounts that would ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considered factors such as payment history and amount, payer coverage, whether there was a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates required significant judgment by management as the Company has limited experience with such factors relating to Aspira GenetiX. In September 2022, the Company received a notice of cancellation from its only Aspira Synergy genetics carrier screening customer, Axia Women’s Health. As a result of this cancellation, along with the general deterioration of commercial opportunities in the genetics carrier screening market, has led the Company to cease providing Aspira GenetiX, including genetics carrier screening, on the Aspira Synergy platform, effective as of September 30, 2022. The Company did not incur any termination penalties nor did the Company accrue any expenses as a result of the cancellation. This did not have a material impact on Company revenues in 2022 or 2023, nor does management expect it to have a material impact in any future periods.
Research And Development Costs	Research and Development Costs Research and development costs are expensed as incurred. Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on behalf of the Company. In addition, acquisitions of assets to be consumed in research and development, with no alternative future use, are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established.
Patent Costs	Patent Costs Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within general and administrative expenses on the Consolidated Statements of Operations. Such costs aggregated to approximately $ 341,000 and $ 410,000 for the years ended December 31, 2023 and 2022, respectively.
2023 Reverse Stock Split	2023 Reverse Stock Split At the Company’s annual meeting on May 9, 2023, the stockholders of the Company approved the proposal to authorize the Board of Directors in its discretion, without further authorization of the Company’s stockholders, to amend the Company’s Certificate of Incorporation to effect a reverse split of the Company’s common stock by a ratio of between one-for-ten and one-for-twenty. On May 9, 2023, the Company’s board of directors approved a one-for-fifteen reverse stock split of the Company’s common stock without any change to its par value, which became effective on May 12, 2023. All references to share and per share amounts for all periods presented in these consolidated financial statements have been retrospectively restated to reflect the Reverse Stock Split and proportional adjustment of the preferred stock conversion ratio. Par values were not adjusted.
Government Assistance	Government Assistance On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). One provision within the CARES Act provided an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable tax credit against the employer share of Social Security tax equal to 50% of the qualified wages paid to employees from March 13, 2020 through December 31, 2020. The ERC was subsequently expanded in 2021 for employers to claim a refundable tax credit for 70% of the qualified wages paid to employees from January 1, 2021 through September 30, 2021. The Company qualified for federal government assistance through the ERC. In August 2023, we received approximately $ 347,000 from the Internal Revenue Service for payroll tax refunds for 2020. The Company recorded the receipt as other income in its consolidated statements of operations.
Contingencies	Contingencies The Company accounts for contingencies in accordance with ASC 450 Contingencies (“ASC 450”) which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Management believes that the Company’s accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized. ASC Topic 740, Accounting for Uncertainty in Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure. The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalent shares outstanding during the period. Common stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share.
Fair Value Of Financial Instruments	Fair Value of Financial Instruments Financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrants and debt. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments. The carrying amount of restricted cash represents a long-term security deposit for a financial arrangement that is at cost. The carrying value of warrants is their fair value at the end of the period. The carrying value of debt approximates fair value due to its interest rate approximating market rates of interest available to the Company for similar instruments.
Leases	Leases The Company determines if a contract, at its inception, is a lease or contains a lease based on whether the contract conveys the right to control the use of identified property, plant, or equipment (an identified asset) for a period of time in exchange for consideration. To determine whether a contract conveys the right to control the use of an identified asset for a period of time, the Company assesses whether, throughout the period of use, it has both the right to obtain substantially all of the economic benefits from use of the identified asset, and the right to direct the use of the identified asset. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease the Company (i) identifies lease and non-lease components, (ii) determines the consideration in the contract, (iii) determines whether the lease is an operating or financing lease; and (iv) recognizes lease right-of-use assets and liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and as such, the Company uses an incremental borrowing rate based on the information available at the lease commencement date, which represents a rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include items such as maintenance, utilities, or other operating costs. For leases of real estate, the Company combines the lease and associated non-lease components in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs. Additionally, the Company has elected the short-term lease exemption and, therefore, does not recognize a right-of-use asset or corresponding liability for lease arrangements with an original term of 12 months or less. Operating leases are included in right-of-use operating assets, current lease liabilities, and noncurrent lease liabilities in the consolidated balance sheet as of December 31, 2023 and 2022.
Segment Reporting	Segment Reporting The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM evaluates the business on a consolidated basis and therefore, the Company operates one operating and reportable segment.

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Accrued Liabilities [Abstract]
Components Of Accrued Liabilities	December 31, December 31, (in thousands) 2023 2022 Payroll and benefits related expenses $ 1,189 $ 1,803 Collaboration and research agreements expenses 217 404 Professional services 951 556 Other accrued liabilities 506 639 Total accrued liabilities $ 2,863 $ 3,402

Property And Equipment (Tables)

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Property And Equipment [Abstract]
Components Of Property And Equipment	Estimated December 31, (in thousands) Useful Life 2023 2022 Machinery and equipment 3 - 5 years $ 363 $ 891 Computer equipment and software 3 years 1,377 1,386 Furniture and fixtures 5 years 189 181 Leasehold improvements (1) 52 721 Gross property and equipment 1,981 3,179 Accumulated depreciation and amortization ( 1,816 ) ( 2,811 ) Property and equipment, net $ 165 $ 368 (1)

Commitments, Contingencies An_2

Commitments, Contingencies And Debt (Tables)	12 Months Ended
	Dec. 31, 2023
Commitments, Contingencies And Debt [Abstract]
Schedule Of Long-Term Debt	December 31, December 31, 2023 2022 (in thousands) DECD loan, net of issuance costs $ 1,596 $ 2,718 Less: Current portion, net of issuance costs ( 166 ) ( 403 ) Total long-term debt, net of issuance costs $ 1,430 $ 2,315
Annual Amounts Of Future Minimum Principal Payments Due Under Certain Contractual Obligations	Payments Due by Period (in thousands) Total 2024 2025 2026 2027 2028 Thereafter DECD Loan $ 1,604 $ 170 $ 335 $ 342 $ 215 $ 129 $ 413 Total $ 1,604 $ 170 $ 335 $ 342 $ 215 $ 129 $ 413
Carrying And Fair Value Of Loan Payable	December 31, December 31, 2023 2022 (in thousands) Fair Value Hierarchy Carrying Value Fair Value Carrying Value Fair Value DECD loan Level 3 $ 1,604 $ 1,255 $ 2,729 $ 2,110
Expense Associated With Operating Leases	Year Ended December 31, Lease Cost Classification 2023 2022 Operating rent expense Cost of revenue $ 83 $ 79 Research and development 63 27 Sales and marketing 11 37 General and administrative 115 66 Variable rent expense Cost of revenue $ 52 $ 39 Research and development 14 22 Sales and marketing 9 34 General and administrative 74 67
Future Lease Payments Related To Operating Leases	Year Payments 2024 $ 194 2025 167 2026 171 2027 84 2028 52 Total Operating Lease Payments 668 Less: Imputed Interest ( 82 ) Present Value of Lease Liabilities 586 Less: Operating Lease Liability, current portion ( 159 ) Operating Lease Liability, non-current portion $ 427
Summary Of Weighted-Average Lease Term And Discount Rate	Year Ended December 31, 2023 2022 Cash paid for amounts included in measurement of lease liabilities: Operating cash outflows relating to operating leases $ 459 $ 362 Weighted-average remaining lease term (in years) 3.6 3.5 Weighted-average discount rate 7.30 % 9.30 %

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2023
Common Stock [Abstract]
Assumptions Used To Estimate Fair Value Of Warrants	December 31, 2023 December 31, 2022 Dividend yield - % - % Volatility 105.1 % 96.8 % Risk-free interest rate 3.93 % 3.99 % Expected lives (years) 3.64 4.64 Weighted average fair value $ 2.064 $ 2.850
Schedule Of Warrants Outstanding	Exercise Price Number of Shares Outstanding under Warrant Issuance Date Expiration Date per Share December 31, 2023 December 31, 2022 August 25, 2022 August 25, 2027 $ 13.20 799,985 799,985 799,985 799,985

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Loss Per Share [Abstract]
Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share	Year Ended December 31, 2023 2022 Numerator: Net Loss $ ( 16,690 ) $ ( 29,885 ) Denominator: Shares used in computing net loss per share, basic and diluted 9,233,306 7,769,109 Net loss per share, basic and diluted $ ( 1.81 ) $ ( 3.85 )
Potential Shares Of Common Stock Excluded From Diluted Loss Per Share Calculation	Year Ended December 31, 2023 2022 Stock options 759,922 655,139 Restricted stock units 59,463 - Warrants 799,985 799,985 Potential common shares 1,619,370 1,455,124

Employee Share Based Compensa_2

Employee Share Based Compensation And Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2023
Employee Share Based Compensation And Benefit Plans [Abstract]
Activity Related to Shares Available for Grant Under the 2000 Plan and 2010 Plan	2010 Stock Option Plan 2019 Stock Option Plan Total Shares available at December 31, 2021 - 248,613 248,613 Options forfeited 2,650 198,625 201,275 Options granted - ( 174,175 ) ( 174,175 ) Restricted stock units forfeited - 346 346 Restricted stock units granted - ( 29,223 ) ( 29,223 ) Shares expired ( 2,650 ) ( 5,754 ) ( 8,404 ) Shares available at December 31, 2022 - 238,432 238,432 Shares added to the plan - 333,333 333,333 Options forfeited 41,950 250,859 292,809 Options granted - ( 397,503 ) ( 397,503 ) Restricted stock units forfeited - - - Restricted stock units granted - ( 259,161 ) ( 259,161 ) Shares expired ( 41,950 ) ( 99 ) ( 42,049 ) Shares available at December 31, 2023 - 165,861 165,861
Stock Option Activity Under 2010 Plan and 2019 Plan	Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term Options outstanding at December 31, 2021 683,861 $ 44.40 $ 3,797,181 7.44 Granted 174,175 14.17 Exercised ( 1,533 ) 8.13 Forfeited ( 201,275 ) 68.12 Options outstanding at December 31, 2022 655,228 $ 29.25 $ - 6.06 Granted 397,503 6.57 Exercised - - Forfeited ( 292,809 ) 28.90 Options outstanding at December 31, 2023 759,922 $ 17.48 $ 113,929 5.37 Shares exercisable: December 31, 2023 452,606 $ 22.57 $ 33,073 3.03 Shares expected to vest: December 31, 2023 201,328 $ 10.31 $ 41,992 8.45
Assumptions Used to Calculate Fair Value of Options Granted Under 2010 Plan	December 31, 2023 December 31, 2022 Dividend yield - % - % Volatility 138.3 % 92.7 % Risk-free interest rate 4.45 % 2.45 % Expected lives (years) 2.00 2.00 Weighted average fair value $ 4.160 $ 7.350
Allocation Of Employee Stock-Based Compensation Expense By Functional Area	Year Ended December 31, (in thousands) 2023 2022 Cost of revenue $ 33 $ 76 Research and development 325 177 Sales and marketing 47 354 General and administrative 1,319 1,807 Total $ 1,724 $ 2,414

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
Components Of Deferred Tax Assets (Liabilities)	Year Ended December 31, (in thousands) 2023 2022 Deferred tax assets: Net operating losses $ 52,540 $ 44,509 Capitalized research expenses 3,432 3,686 Fixed asset depreciation 487 678 Other 697 804 ASC 842 Right of Use Liability 137 - Total deferred tax assets 57,293 49,677 Valuation allowance ( 57,170 ) ( 49,677 ) Deferred tax assets $ 123 $ - Deferred tax liabilities: ASC 842 Right of Use Asset $ ( 123 ) $ - Deferred tax liabilities $ ( 123 ) $ - Net deferred tax asset $ - $ -
Reconciliation Of Statutory Federal Income Tax Rate	Year Ended December 31, 2023 2022 Tax at federal statutory rate 21 % 21 % State tax, net of federal benefit - 5 Change in valuation allowance ( 17 ) ( 26 ) Change in warrant valuation 1 1 Net operating loss reduction due to Section 382 limitation ( 1 ) - Permanent items ( 1 ) ( 1 ) Deferred Adjustments, Return to Provision ( 3 ) - Effective income tax rate - % - %
Reconciliation Of Change In Unrecognized Tax Benefits	(in thousands) Federal Tax State Tax Total Balance at December 31, 2021 $ 4,937 $ 5,644 $ 10,581 Return to provision true up - - - Increase in tax position during 2022 223 212 435 Decrease due to expirations during 2022 ( 785 ) - ( 785 ) Balance at December 31, 2022 $ 4,375 $ 5,856 $ 10,231 Return to provision true up - - - Increase in tax position during 2023 282 211 493 Decrease due to expirations during 2023 - - - Balance at December 31, 2023 $ 4,657 $ 6,067 $ 10,724

Basis Of Presentation And Sum_3

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) segment	Dec. 31, 2022 USD ($)
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Market capitalisation	$ 35,000,000
Accumulated deficit	(518,303,000)	$ (501,613,000)
Patent costs	$ 341,000	410,000
Number of reportable segments | segment	1
Working capital	$ 200,000
Net loss	(16,690,000)	(29,885,000)
Net cash used in operating activities	(15,894,000)	(31,068,000)
Receivable impairment	0	$ 0
Government assistance amount	$ 347,000
Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]	Nonoperating Income Expense
Minimum [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life	3 years
Maximum [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life	5 years

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Recent Accounting Pronouncements [Abstract]
Operating lease right-of-use assets	$ 528	$ 282
Operating lease liability	586
Accumulated deficit	$ (518,303)	$ (501,613)

Strategic Alliance With Quest_2

Strategic Alliance With Quest Diagnostics Incorporated (Details)	12 Months Ended
	Dec. 31, 2023 USD ($)
Line of Credit Facility [Line Items]
Accounts payable and accrued liabilities	$ 346,820
Quest Diagnostics [Member] | Amended Agreement [Member]
Line of Credit Facility [Line Items]
Annual fee to services of Part-time Quest Diagnostics project manager	$ 75,000

Property And Equipment (Narrati

Property And Equipment (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property And Equipment [Abstract]
Depreciation expense for property and equipment	$ 199,000	$ 265,000
Impairment	$ 0	$ 52,000
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]		General And Administrative Expense

Property And Equipment (Compone

Property And Equipment (Components Of Property And Equipment) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 1,981	$ 3,179
Accumulated depreciation and amortization	(1,816)	(2,811)
Property and equipment, net	$ 165	368
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 363	891
Machinery And Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Machinery And Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 1,377	1,386
Estimated useful life	3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 189	181
Estimated useful life	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 52	$ 721

Accrued Liabilities (Components

Accrued Liabilities (Components Of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accrued Liabilities [Abstract]
Payroll and benefits related expenses	$ 1,189	$ 1,803
Collaboration and research agreements expenses	217	404
Professional services	951	556
Other accrued liabilities	506	639
Total accrued liabilities	$ 2,863	$ 3,402

Commitments, Contingencies An_3

Commitments, Contingencies And Debt (Narrative) (Details) $ in Thousands				12 Months Ended
	Dec. 03, 2020 USD ($)	Apr. 15, 2016 USD ($)	Mar. 22, 2016 USD ($)	Dec. 31, 2024	Dec. 31, 2023 USD ($) item	Dec. 31, 2022 USD ($)
Commitments And Contingencies [Line Items]
Other income					$ 1,000
Proceeds from DECD loan					1,177
Amended Loan Agreement [Member].
Commitments And Contingencies [Line Items]
Unamortized debt issuance costs					8
Debt instrument carrying amount					670
DECD Loan [Member]
Commitments And Contingencies [Line Items]
Proceeds from loan	$ 2,000	$ 2,000
Maximum loan forgiveness amount under loan agreement			$ 1,500
Line of Credit, reduction in principal amount					$ 1,000
Percentage of penalty included in loan agreement			5%
Line of credit, maturity date					Apr. 15, 2026
Line of credit, maximum borrowing capacity					$ 4,000
Line of credit fixed interest rate			2%
DECD Loan [Member] | Loan Agreement Target Employment Milestone [Member]
Commitments And Contingencies [Line Items]
Proceeds from loan	$ 1,000
Insurance Promissory Notes [Member]
Commitments And Contingencies [Line Items]
Debt instrument interest rate					7.79%	5.48%
Maturity date					Oct. 01, 2023
Aggregate principal amount outstanding					$ 670	$ 764
Notes payable number of monthly payment installment | item					10
Notes payable frequency of periodic payment, description					monthly
Insurance Promissory Notes [Member] | Forecast [Member]
Commitments And Contingencies [Line Items]
Maturity date				Oct. 01, 2024

Commitments, Contingencies An_4

Commitments, Contingencies And Debt (Operating Leases) (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Austin, Texas facility
Commitments And Contingencies [Line Items]
Lease expiration date	Feb. 28, 2027
Lease renewal term	37 months
Operating lease term	12 months
Lessee, Operating Lease, Option to Extend	option to extend the lease for an additional three years
Annual base rent	$ 58	$ 114
Variable Lease, Cost	$ 32	$ 54
Palo Alto, California [Member]
Commitments And Contingencies [Line Items]
Lease expiration date	May 31, 2024
Lessee, Operating Lease, Option to Extend	no option for renewal with the sublessor

Commitments, Contingencies An_5

Commitments, Contingencies And Debt (Non-Cancellable Royalty Obligations And Business Agreements) (Narrative) (Details) - USD ($)		3 Months Ended		6 Months Ended	12 Months Ended			17 Months Ended
	Aug. 08, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023
Commitments And Contingencies [Line Items]
Royalty expense						$ 324,000	$ 318,000
Research and development						4,035,000	5,917,000
Insurance reimbursement						523,000
Severance Costs						$ 1,284,000
Research Collaboration Agreement With Johns Hopkins University School Of Medicine [Member]
Commitments And Contingencies [Line Items]
Percent of royalty paid						4%
Royalty payments						$ 57,500
Research and development						215,000
Sponsored Research Agreement With Multiple Entities [Member]
Commitments And Contingencies [Line Items]
Agreement amount	$ 1,252,000
Agreement amount, percent paid or payable			68%
Research and development							$ 868,000	$ 1,083,000
Payments of Research agreements								$ 1,040,000
License Agreement With Multiple Entities [Member]
Commitments And Contingencies [Line Items]
Initial license fee						75,000
Annual license fee						50,000
Completion of certain deliverables, first [Member] | Sponsored Research Agreement With Multiple Entities [Member]
Commitments And Contingencies [Line Items]
Agreement amount, percent paid or payable		15%
Forecast [Member] | Research and Development Arrangement [Member]
Commitments And Contingencies [Line Items]
Additional Payements					$ 212,000
Forecast [Member] | Sponsored Research Agreement With Multiple Entities [Member]
Commitments And Contingencies [Line Items]
Agreement amount, percent paid or payable				17%
Maximum [Member] | License Agreement With Multiple Entities [Member]
Commitments And Contingencies [Line Items]
Royalty expense						$ 1,350,000

Commitments, Contingencies An_6

Commitments, Contingencies And Debt (Schedule Of Long-Term Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Commitments, Contingencies And Debt [Abstract]
DECD loan, net of issuance costs	$ 1,596	$ 2,718
Less: Current portion, net of issuance costs	(166)	(403)
Total long-term debt, net of issuance costs	$ 1,430	$ 2,315

Commitments, Contingencies An_7

Commitments, Contingencies And Debt (Annual Amounts Of Future Minimum Principal Payments Due Under Certain Contractual Obligations) (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
Contractual obligation, 2023	$ 170
Contractual obligation, 2024	335
Contractual obligation, 2025	342
Contractual obligation, 2026	215
Contractual obligation, 2027	129
Contractual obligation, Thereafter	413
Total	1,604
DECD Loan [Member]
Debt Instrument [Line Items]
Contractual obligation, 2023	170
Contractual obligation, 2024	335
Contractual obligation, 2025	342
Contractual obligation, 2026	215
Contractual obligation, 2027	129
Contractual obligation, Thereafter	413
Total	$ 1,604

Commitments, Contingencies An_8

Commitments, Contingencies And Debt (Carrying And Fair Value Of Loan Payable) (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
DECD loan, Carrying value	$ 1,604	$ 2,729
DECD loan, Fair value	$ 1,255	$ 2,110

Commitments, Contingencies An_9

Commitments, Contingencies And Debt (Expense Associated With Operating Leases) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cost Of Revenue [Member]
Lessee, Lease, Description [Line Items]
Operating rent expense	$ 83	$ 79
Variable rent expense	52	39
Research And Development [Member]
Lessee, Lease, Description [Line Items]
Operating rent expense	63	27
Variable rent expense	14	22
Sales And Marketing [Member]
Lessee, Lease, Description [Line Items]
Operating rent expense	11	37
Variable rent expense	9	34
General And Administrative [Member]
Lessee, Lease, Description [Line Items]
Operating rent expense	115	66
Variable rent expense	$ 74	$ 67

Commitments, Contingencies A_10

Commitments, Contingencies And Debt (Future Lease Payments Related To Operating Leases) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Commitments, Contingencies And Debt [Abstract]
2024	$ 194
2025	167
2026	171
2027	84
2028	52
Total Operating Lease Payments	668
Less: Imputed Interest	(82)
Present Value of Lease Liabilities	586
Less: Operating Lease Liability, current portion	(159)	$ (77)
Operating Lease Liability, non-current portion	$ 427	$ 272

Commitments, Contingencies A_11

Commitments, Contingencies And Debt (Summary Of Weighted-Average Lease Term And Discount Rate) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Commitments, Contingencies And Debt [Abstract]
Operating cash outflows relating to operating leases	$ 459	$ 362
Weighted-average remaining lease term (in years)	3 years 7 months 6 days	3 years 6 months
Weighted-average discount rate	7.30%	9.30%

Common Stock (Narrative) (Detai

Common Stock (Narrative) (Details) - USD ($)						9 Months Ended	12 Months Ended
	Jan. 24, 2024	Jul. 20, 2023	Mar. 28, 2023	Feb. 10, 2023	Aug. 22, 2022	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Jan. 26, 2024	Jan. 26, 2023
Common Stock Equity [Line Items]
Common stock, shares authorized							200,000,000	150,000,000
Common stock, par value							$ 0.001	$ 0.001
Costs related to issuance of common stock							$ 134,000
Proceeds from sale of common stock							$ 202,000
Exercise price of warrants					$ 13.20					$ 13.20
Shares of common stock called by warrants							366,664
Warrant term							5 years
Fair value of warrants							$ 1,651,000	$ 2,280,000
Warrants Issued, Fair Value								$ 3,984,000
Common Stock [Member]
Common Stock Equity [Line Items]
Common Stock And Warrants Issued, Shares								800,000
Common stock shares issued							35,552
2022 Offering [Member]
Common Stock Equity [Line Items]
Common stock, par value					$ 0.001
Common stock shares issued					800,000
Proceeds from sale of common stock					$ 7,675,000
Stock issuance expenses, net equity impact								$ 751,000
Debt Issuance Costs, Gross					$ 1,325,000
Stock price per share					$ 11.25
Warrants, offering costs					$ 574,000
Common stock issuable per warrant					799,985
Shares of common stock called by warrants					1
Fair value of warrants							$ 1,651,000	2,280,000
Proceeds from issuance of equity					$ 9,000,000
Warrants Issued, Fair Value					$ 3,984,000
Placement Shares [Member]
Common Stock Equity [Line Items]
Common stock, par value				$ 0.001
Common stock shares issued							35,552
Proceeds from sale of common stock							$ 211,000
Stock issuance expenses, net equity impact						$ 134,000
Prepaid Stock Issuance Costs							$ 0	150,000
Stock Offering, Maximum Aggregate Price				$ 12,500,000
General and administrative expense								143,000,000
Placement Shares [Member] | Additional Paid-In Capital
Common Stock Equity [Line Items]
Additional paid in capital								$ 7,000,000
Purchase Shares [Member]
Common Stock Equity [Line Items]
Common stock, par value			$ 0.001
Common stock shares issued							360,943
Proceeds from sale of common stock							$ 1,177,000
Stock Issuance Expenses							329,000
Stock Offering, Maximum Aggregate Price			$ 10,000,000
Maximum amount per purchase			$ 1,000,000
Stock issued for services							258,000
Legal expenses							41,000
Purchase agreement term			36 months
Purchase Agreement [Member]
Common Stock Equity [Line Items]
Common stock, par value		$ 0.001
Common stock shares issued		1,694,820
Stock Issuance Expenses		$ 597,000
Proceeds from public offering		$ 4,700,000
Purchase Agreement [Member] | Purchasers [Member]
Common Stock Equity [Line Items]
Common stock shares issued		1,650,473
Share Price		$ 2.75
Purchase Agreement [Member] | Directors And Executive Officers [Member]
Common Stock Equity [Line Items]
Common stock shares issued		44,347
Share Price		$ 3.98
Lincoln Park Capital Fund [Member] | Purchase Shares [Member]
Common Stock Equity [Line Items]
Stock Transaction Costs							$ 30,000
Alliance Global Partners [Member]
Common Stock Equity [Line Items]
Legal expenses		$ 75,000
Placement agent cash fee paid		0.07%
Non-accountable expense allowance		$ 30,000
Alliance Global Partners [Member] | Purchasers [Member]
Common Stock Equity [Line Items]
Common stock shares issued		182,447
Alliance Global Partners [Member] | Directors And Executive Officers [Member]
Common Stock Equity [Line Items]
Placement agent cash fee paid		0.035%
Below $0.50 [Member]
Common Stock Equity [Line Items]
Maximum number of shares per purchase			6,667
$0.50 To $0.74 [Member] | Purchase Shares [Member]
Common Stock Equity [Line Items]
Share Price			$ 7.50
Maximum number of shares per purchase			13,333
$0.75 To $1.00 [Member] | Purchase Shares [Member]
Common Stock Equity [Line Items]
Share Price			$ 11.25
Maximum number of shares per purchase			16,666
$1.00 And Above [Member] | Purchase Shares [Member]
Common Stock Equity [Line Items]
Share Price			$ 15
Maximum number of shares per purchase			20,000
Minimum [Member]
Common Stock Equity [Line Items]
Warrant restriction, threshold common stock held, percent							4.99%
Maximum [Member]
Common Stock Equity [Line Items]
Warrant restriction, threshold common stock held, percent							9.99%
Subsequent Event
Common Stock Equity [Line Items]
Exercise price of warrants	$ 0.0001								$ 4.13
Shares of common stock called by warrants	200,000
Warrant restriction, threshold common stock held, percent	9.99%
Subsequent Event | Purchasers [Member]
Common Stock Equity [Line Items]
Exercise price of warrants	$ 4.13
Warrant term	5 years
Subsequent Event | Purchase Agreement [Member]
Common Stock Equity [Line Items]
Common stock, par value	$ 0.001
Common stock shares issued	1,371,000
Stock Issuance Expenses	$ 941,000
Proceeds from public offering	$ 5,500,000
Subsequent Event | Purchase Agreement [Member] | Purchasers [Member]
Common Stock Equity [Line Items]
Common stock shares issued	1,368,600
Share Price	$ 3.50
Subsequent Event | Alliance Global Partners [Member]
Common Stock Equity [Line Items]
Legal expenses	$ 75,000
Placement agent cash fee paid	7%
Non-accountable expense allowance	$ 30,000

Common Stock (Assumptions Used

Common Stock (Assumptions Used to Estimate Fair Value of Warrants) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Volatility	138.30%	92.70%
Risk-free interest rate	4.45%	2.45%
Expected lives (years)	2 years	2 years
2022 Offering [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Volatility	105.10%	96.80%
Risk-free interest rate	3.93%	3.99%
Expected lives (years)	3 years 7 months 20 days	4 years 7 months 20 days
Weighted average fair value	$ 2.064	$ 2.850

Common Stock (Schedule Of Warra

Common Stock (Schedule Of Warrants Outstanding) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Jan. 26, 2023	Dec. 31, 2022	Aug. 22, 2022
Class of Warrant or Right [Line Items]
Exercise Price per Share		$ 13.20		$ 13.20
Number of Shares Outstanding under Warrant	799,985		799,985
Period 1
Class of Warrant or Right [Line Items]
Issuance Date	Aug. 25, 2022
Expiration Date	Aug. 25, 2027
Exercise Price per Share	$ 13.20
Number of Shares Outstanding under Warrant	799,985		799,985

Loss Per Share (Reconciliation

Loss Per Share (Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Loss (Numerator)
Net loss	$ (16,690)	$ (29,885)
Shares (Denominator)
Shares used in computing net loss per share, basic	9,233,306	7,769,109
Shares used in computing net loss per share, diluted	9,233,306	7,769,109
Per Share Amount
Net loss per share - basic	$ (1.81)	$ (3.85)
Net loss per share - diluted	$ (1.81)	$ (3.85)

Loss Per Share (Potential Share

Loss Per Share (Potential Shares Of Common Stock Excluded From Diluted Loss Per Share Calculation) (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	759,922	655,139
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	59,463
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	799,985	799,985
Potential Shares Of Aspira Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	1,619,370	1,455,124

Employee Share Based Compensa_3

Employee Share Based Compensation And Benefit Plans (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	May 09, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	165,861	238,432	248,613
Weighted average period over which unrecognized cost expected to be recognized	6 months
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value	$ 0	$ 5,000,000
Total Fair Value of Vested Options	$ 6,073,000,000	5,982,000,000
401(k) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
401(k) Plan, percentage for employee maximum contribution amount	90%
401(k) employer contributions		$ 0	$ 0
Unvested Stock Option Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation costs related to nonvested stock option awards	$ 677,000
Weighted average period over which unrecognized cost expected to be recognized	1 year 9 months 21 days
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation costs related to nonvested stock option awards	$ 104,000
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	0
2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	165,861
Share based compensation shares authorized for grants	699,485			1,032,818
Common Stock Subject to Outstanding Stock Options [Member] | 2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	245,154
Common Stock Subject to Outstanding Stock Options [Member] | 2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	514,768
Common Stock Subject to Outstanding Stock Options [Member] | 2019 Stock Incentive Plan [Member] | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	59,463

Employee Share Based Compensa_4

Employee Share Based Compensation And Benefit Plans (Activity Related to Shares Available for Grant Under the 2010 Plan and 2019 Plan) (Details) - shares		12 Months Ended
	May 12, 2023	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period		238,432	248,613
Options forfeited		292,809	201,275
Options granted		(397,503)	(174,175)
Restricted stock units forfeited			(346)
Restricted stock units granted		(259,161)	(29,223)
Shares expired		(42,049)	(8,404)
Shares added to plan		333,333
Shares available at end of period		165,861	238,432
2010 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options forfeited		41,950	2,650
Shares expired		(41,950)	(2,650)
2019 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period		238,432	248,613
Options forfeited		250,859	198,625
Options granted		(397,503)	(174,175)
Restricted stock units forfeited			(346)
Restricted stock units granted		(259,161)	(29,223)
Shares expired		(99)	(5,754)
Shares added to plan		333,333
Shares available at end of period		165,861	238,432
2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized	333,333
Shares available at end of period		165,861

Employee Share Based Compensa_5

Employee Share Based Compensation And Benefit Plans (Stock Option Activity Under 2010 Plan and 2019 Plan) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Number of Shares
Options outstanding	655,228	683,861
Granted	397,503	174,175
Exercised		(1,533)
Canceled	(292,809)	(201,275)
Options outstanding	759,922	655,228	683,861
Shares exercisable	452,606
Shares expected to vest	201,328
Weighted Average Exercise Price
Options outstanding	$ 29.25	$ 44.40
Granted	6.57	14.17
Exercised		8.13
Canceled	28.90	68.12
Options outstanding	17.48	$ 29.25	$ 44.40
Shares exercisable	22.57
Shares expected to vest	$ 10.31
Aggregate Intrinsic Value
Options outstanding	$ 113,929		$ 3,797,181
Shares exercisable	33,073
Shares expected to vest	$ 41,992
Weighted Average Remaining Contractual Term
Options outstanding	5 years 4 months 13 days	6 years 21 days	7 years 5 months 8 days
Shares exercisable	3 years 10 days
Shares expected to vest	8 years 5 months 12 days
Total Intrinsic Value of Options Exercised	$ 0	$ 5,000

Employee Share Based Compensa_6

Employee Share Based Compensation And Benefit Plans (Assumptions Used to Estimate Fair Value of Warrants) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Stockholders' Equity (Deficit) [Abstract]
Volatility	138.30%	92.70%
Risk-free interest rate	4.45%	2.45%
Expected lives (years)	2 years	2 years
Weighted average fair value	$ 4.160	$ 7.350

Employee Share Based Compensa_7

Employee Share Based Compensation And Benefit Plans (Allocation of Employee and Director Stock-Based Compensation Expense by Functional Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,724	$ 2,414
Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	33	76
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	325	177
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	47	354
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,319	$ 1,807

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Taxes [Line Items]
Current income tax expense (benefit)	$ 0	$ 0
Domestic and foreign components of loss from continuing operations before income taxes	16,700,000	29,900,000
Deferred income tax expense (benefit)	0	0
Valuation allowance	57,170,000	49,677,000
Interest and penalties as a result of uncertain tax positions	0	0
Gross unrecognized tax benefits	10,724,000	10,231,000	$ 10,581,000
Prior To 2018 [Member]
Income Taxes [Line Items]
Operating loss carryforwards		67,000,000
Operating loss, net carryforwards expiration amount		31,000,000
2018 And Forward [Member]
Income Taxes [Line Items]
Operating loss carryforwards	116,000,000
Research and Development Credits [Member]
Income Taxes [Line Items]
Operating loss carryforwards	4,400,000	5,900,000
Gross unrecognized tax benefits	10,700,000
Total Unrecognized income tax benefit, affecting effective tax rate if recognized	10,700,000
Federal Tax [Member]
Income Taxes [Line Items]
Increase in valuation allowance	7,500,000
Gross unrecognized tax benefits	4,657,000	$ 4,375,000	$ 4,937,000
Minimum [Member] | Prior To 2018 [Member]
Income Taxes [Line Items]
Operating loss carryforwards expiration date		Dec. 31, 2024
Minimum [Member] | 2018 And Forward [Member]
Income Taxes [Line Items]
Operating loss carryforwards expiration date		Dec. 31, 2024
Maximum [Member] | Prior To 2018 [Member]
Income Taxes [Line Items]
Operating loss carryforwards expiration date		Dec. 31, 2037
Maximum [Member] | 2018 And Forward [Member]
Income Taxes [Line Items]
Operating loss carryforwards expiration date		Dec. 31, 2043
Additional [Member] | Federal Tax [Member] | Research and Development Credits [Member]
Income Taxes [Line Items]
Operating loss carryforwards	300,000
Additional [Member] | California State | Research and Development Credits [Member]
Income Taxes [Line Items]
Operating loss carryforwards	$ 200,000

Income Taxes (Components Of Def

Income Taxes (Components Of Deferred Tax Assets (Liabilities)) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Net operating losses	$ 52,540	$ 44,509
Capitalized research expense	3,432	3,686
Fixed asset depreciation	487	678
Other	697	804
ASC 842 Right of Use Liability	137
Total deferred tax assets	57,293	49,677
Valuation allowance	(57,170)	(49,677)
Deferred tax assets	123
Deferred tax liabilities:
ASC 842 Right of Use Asset	(123)
Deferred tax liabilities	(123)
Net deferred tax asset

Income Taxes (Reconciliation Of

Income Taxes (Reconciliation Of Statutory Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Taxes [Abstract]
Tax at federal statutory rate	21%	21%
State tax, net of federal benefit		5%
Valuation allowance	(17.00%)	(26.00%)
Change in warrant valuation	1%	1%
Net operating loss reduction due to Section 382 limitation	(1.00%)
Permanent items	(1.00%)	(1.00%)
Deferred Adjustments, Return to Provision	(3.00%)
Effective Income Tax Rate Reconciliation, Percent, Total

Income Taxes (Reconciliation _2

Income Taxes (Reconciliation Of Change In Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Contingency [Line Items]
Beginning Balance	$ 10,231	$ 10,581
Increase in tax position	493	435
Decrease due to expirations		(785)
Ending Balance	10,724	10,231
Federal Tax [Member]
Income Tax Contingency [Line Items]
Beginning Balance	4,375	4,937
Increase in tax position	282	223
Decrease due to expirations		(785)
Ending Balance	4,657	4,375
State and Local Jurisdiction
Income Tax Contingency [Line Items]
Beginning Balance	5,856	5,644
Increase in tax position	211	212
Ending Balance	$ 6,067	$ 5,856

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) - USD ($)			12 Months Ended
	Jan. 24, 2024	Jul. 20, 2023	Dec. 31, 2023	Dec. 31, 2022	Jan. 26, 2024	Jan. 26, 2023	Aug. 22, 2022
Subsequent Event [Line Items]
Common stock, par value			$ 0.001	$ 0.001
Shares of common stock called by warrants			366,664
Exercise price of warrants						$ 13.20	$ 13.20
Market capitalisation			$ 35,000,000
Warrant term			5 years
Fixed lease payment			$ 459,000	$ 362,000
Common Stock [Member]
Subsequent Event [Line Items]
Common stock shares issued			35,552
Purchase Agreement [Member]
Subsequent Event [Line Items]
Common stock, par value		$ 0.001
Proceeds from public offering		$ 4,700,000
Stock issuance expenses		$ 597,000
Common stock shares issued		1,694,820
Purchase Agreement [Member] | Directors And Executive Officers [Member]
Subsequent Event [Line Items]
Common stock shares issued		44,347
Share Price		$ 3.98
Purchase Agreement [Member] | Purchasers [Member]
Subsequent Event [Line Items]
Common stock shares issued		1,650,473
Share Price		$ 2.75
Subsequent Event
Subsequent Event [Line Items]
Shares of common stock called by warrants	200,000
Exercise price of warrants	$ 0.0001				$ 4.13
Warrant restriction, threshold common stock held, percent	9.99%
Shares issued price per share deduction	$ 0.0001
Subsequent Event | Purchasers [Member]
Subsequent Event [Line Items]
Exercise price of warrants	$ 4.13
Warrant term	5 years
Subsequent Event | Common Stock [Member] | Chief Executive Officer [Member]
Subsequent Event [Line Items]
Share Price	$ 4.13
Subsequent Event | Purchase Agreement [Member]
Subsequent Event [Line Items]
Common stock, par value	$ 0.001
Proceeds from public offering	$ 5,500,000
Stock issuance expenses	$ 941,000
Common stock shares issued	1,371,000
Subsequent Event | Purchase Agreement [Member] | Chief Executive Officer [Member]
Subsequent Event [Line Items]
Common stock shares issued	2,400
Stock price per share	$ 4.2555
Subsequent Event | Purchase Agreement [Member] | Purchasers [Member]
Subsequent Event [Line Items]
Common stock shares issued	1,368,600
Share Price	$ 3.50
Subsequent Event | Purchase Agreement [Member] | Common Stock [Member] | Chief Executive Officer [Member]
Subsequent Event [Line Items]
Share Price	$ 4.13
Subsequent Event | Purchase Warrants [Member]
Subsequent Event [Line Items]
Shares of common stock called by warrants	1,571,000
Share Price	$ 0.125
Minimum [Member]
Subsequent Event [Line Items]
Warrant restriction, threshold common stock held, percent			4.99%
Maximum [Member]
Subsequent Event [Line Items]
Warrant restriction, threshold common stock held, percent			9.99%
Alliance Global Partners [Member]
Subsequent Event [Line Items]
Legal expenses		$ 75,000
Non-accountable expense allowance		$ 30,000
Placement agent cash fee paid		0.07%
Alliance Global Partners [Member] | Directors And Executive Officers [Member]
Subsequent Event [Line Items]
Placement agent cash fee paid		0.035%
Alliance Global Partners [Member] | Purchasers [Member]
Subsequent Event [Line Items]
Common stock shares issued		182,447
Alliance Global Partners [Member] | Subsequent Event
Subsequent Event [Line Items]
Legal expenses	$ 75,000
Non-accountable expense allowance	$ 30,000
Placement agent cash fee	3.50%
Placement agent cash fee paid	7%